Document:

EX-10.2

 Exhibit 10.2 

TECHNICAL TRANSFER AND SERVICE AGREEMENT 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 
 TECHNICAL
TRANSFER AND SERVICE AGREEMENT 
 This TECHNICAL TRANSFER AND SERVICE AGREEMENT (this “Agreement”), dated
as of July 31, 2015 (the “Effective Date”), is made by and between Flexion Therapeutics, Inc., a Delaware corporation having its principal place of business at 10 Mall Road, Suite 301, Burlington, Massachusetts, United States
(“Flexion”), and Patheon UK Limited, a company incorporated in England and Wales having its principal place of business at Kingfisher Drive, Covingham, Swindon, SN35BZ, United Kingdom (“Patheon”). Flexion and
Patheon are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS,
Flexion has a commercial interest in the Manufacture (as defined herein) and commercialization of FX006 drug product, an extended-release formulation of triamcinolone acetonide (TCA) which is manufactured using Flexion’s Manufacturing Process
(the “Product”); 
 WHEREAS, concurrently herewith, the Parties are executing a manufacturing and supply agreement (the
“Manufacturing and Supply Agreement”) pursuant to which Patheon would be a manufacturer and supplier of the Product; and 

WHEREAS, in anticipation of the Manufacturing and Supply Agreement and the goods and services that Patheon will supply thereunder, the Parties
desire to enter into a binding agreement pursuant to which Patheon would undertake certain technical transfer and construction services in order to validate and scale up portions of Flexion’s technology package and prepare Patheon’s
facilities for the Manufacture of the Product; 
 NOW, THEREFORE, in consideration of the foregoing, the mutual promises and covenants of
the Parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 The
following terms will have the meanings set forth below. Unless the context indicates otherwise, the singular will include the plural and the plural will include the singular. Any term not defined hereunder shall have the meaning ascribed to such
term in the Manufacturing and Supply Agreement. 
 1.1 “Act” means the United States Federal Food, Drug and Cosmetic Act,
as amended. 
 1.2 “Additional Services” means any services requested and approved by Flexion that supplement
Patheon’s regular performance of the Services as described in Schedule 2.1(a) of the Manufacturing and Supply Agreement. 
 1.3
“Affiliate(s)” means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common 

  
 1 

 
control with, such Person. For the purposes of this Section 1.3 only, a Person will be regarded as in control of another Person if such Person owns, or directly or indirectly controls, more
than 50% of the voting securities (or comparable equity interests) or other ownership interests of the other Person, or if such Person directly or indirectly possesses the power to direct or cause the direction of the management or policies of the
other Person, whether through the ownership of voting securities, by contract, or any other means whatsoever. 
 1.4
“Agreement” has the meaning set forth in the preamble hereto. 
 1.5 “API” means the active pharmaceutical
ingredient triamcinolone acetonide, micronized. 
 1.6 “Applicable Law” means applicable United States, Canadian, English
and other foreign federal, state, and local laws, orders, rules, regulations, guidelines, standards, customs and ordinances, including, without limitation, those (to the extent they are applicable) of the FDA, Health Canada, the Medicines and
Healthcare Products Regulatory Agency in the United Kingdom and other comparable foreign Regulatory Authorities, including the Food Drug and Cosmetic Act. 

1.7 “Base Fee” means the monthly fee paid by Flexion in consideration for the Services, as more specifically set forth in
Schedule 2.1(a) of the Manufacturing and Supply Agreement. For the avoidance of doubt, Base Fees do not include Capital Expenditures, Product Fees (as defined in the Manufacturing and Supply Agreement), Material Costs (as defined in the
Manufacturing and Supply Agreement), or charges for Bill Back Items or Additional Services. 
 1.8 “Bill Back Items” means
items and services set forth in Schedule 2.1(a) of the Manufacturing and Supply Agreement that are used or necessary in connection with the Manufacture of the Products and which result in a nominal cost to Flexion. 

1.9 “Capital Expenditures” has the meaning set forth in Section 2.2. 

1.10 “Certificate of Analysis” has the meaning set forth in Section 1.8a of the Manufacturing and Supply Agreement. 

1.11 “Change of Control” has the meaning set forth in Section 9.6. 

1.12 “Claim” has the meaning set forth in Section 7.3(a). 

1.13 “Completion of the Tech Transfer” has the meaning set forth in Section 8.2. 

1.14 “Control” or “Controlled” means ownership or the right by a Party to assign or grant a license or
sublicense under intellectual property rights to the other Party of the scope set forth herein, without breaching the terms of any agreement with a Third Party. 

1.15 “Discretionary Manufacturing Changes” has the meaning set forth in Exhibit 2.1-F. 

1.16 “Effective Date” has the meaning set forth in the Preamble. 

  
 2 

 1.17 “EMA” means the European Medicines Agency. 

1.18 “Equipment” means any equipment used in the Manufacture of the Product as more fully set forth in Section 2.9 of
the Manufacturing and Supply Agreement. 
 1.19 “Exploit” means to make, have made, import, use, sell, offer for sale,
receive or otherwise dispose of the Product or process, including the research, development (including the conduct of clinical trials), registration, modification, enhancement, improvement, Manufacture, storage, formulation, optimization, export,
transport, distribution, promotion, or marketing of the Product or process. 
 1.20 “Facility” means the facility of
Patheon located at Kingfisher Drive, Swindon, Wiltshire SN3 5BZ, United Kingdom. 
 1.21 “FDA” means the United States Food
and Drug Administration and any successor organization thereto and all agencies under its direct control. 
 1.22 “Flexion”
has the meaning set forth in the Preamble. 
 1.23 “Flexion Indemnified Parties” has the meaning set forth in
Section 7.2. 
 1.24 “Flexion Manufacturing Equipment” has the meaning set forth in Exhibit 2.1-F. 

1.25 “Flexion’s Manufacturing Process” means the proprietary process owned or Controlled by Flexion for Manufacturing
the Product as disclosed by Flexion to Patheon, and each intermediate of the Product, as established as of the Effective Date, including, without limitation, as set forth in the investigational new drug application filed with the FDA
(“IND”) and, when applicable, as set forth in the NDA as may be filed with, and approved by, the FDA. 
 1.26
“Flexion On Site Representative” has the meaning set forth in Section 0(a). 
 1.27 “GMP” means the
current good manufacturing practices applicable from time to time to the Manufacturing of the Product, or any intermediate of the Product, pursuant to Applicable Law, including those promulgated under the Act at 21 C.F.R. (chapters 210 and 211), and
those promulgated under EC Directive 2003/94/EC, together with the latest FDA and EMA guidance documents pertaining to manufacturing and quality control practices, all as updated, amended and revised from time to time. 

1.28 “Indemnification Claim Notice” has the meaning set forth in Section 7.3(a). 

1.29 “Indemnified Party” has the meaning set forth in Section 7.3(a). 

1.30 “Indemnifying Party” has the meaning set forth in Section 7.3(a). 

1.31 “Key Technical Assumptions” has the meaning set forth in Exhibit 2.1-D. 

1.32 “Loss” means any claims, lawsuits, losses, damages, liabilities, penalties, costs, and expenses (including reasonable
attorneys’ fees and disbursements). 

  
 3 

 1.33 “Maintenance” means the maintenance of Equipment and Facilities in
satisfactory operating condition, including the performance of systematic inspection and service of Equipment pursuant to the applicable Standard Operating Procedures of Patheon, as reviewed and agreed to by Flexion (the “Equipment Standard
Operating Procedures”), or the manufacturer’s terms of operation and recommended procedures. 
 1.34 “Make Good
Costs” has the meaning set forth in Section 8.11(c). 
 1.35 “Manufacture” and “Manufacturing
Services” means the manufacturing, processing, formulating, sterilization, filling, packaging, labelling, storage, handling, and quality control testing of Materials or the Product as more particularly set out in Schedule 2.1(a)
of the Manufacturing and Supply Agreement. 
 1.36 “Manufacturing and Supply Agreement” has the meaning set forth in the
Recitals. 
 1.37 “Manufacturing Suite” means the manufacturing suite at the Facility capable of Manufacturing the Product
pursuant to Flexion’s Manufacturing Process, whose footprint is attached as Exhibit 2.1-A, together with the areas identified in the plan attached as Exhibit 2.1-A as the areas for the bulk powder Manufacture and bulk vial filling and, pursuant
to the terms of Section 2.10 of the Manufacturing and Supply Agreement, the Phase I Filling Space. The footprint of the Manufacturing Suite and the engineering approach shall be revised by the Parties in order to adapt the Manufacturing Suite
to Flexion’s Manufacturing Process, as set forth in Section 2.1 hereto. Such footprint is diagrammatic in nature and is intended to generally depict the location and approximate size of current and future spaces allocated to Flexion. Such
footprint may be amended to be specifically adapted to the Manufacture of the Product, and the Parties shall agree upon the definitive footprint, taking into account parameters such as the exact design of the space, space classifications, code
requirements, equipment, materials, personnel, waste stream process flows, equipment sizing and utility requirements. For purposes of clarity, prior to the Phase III Manufacturing Suite Clearance Date (as defined in Section 2.10 of the
Manufacturing and Supply Agreement), the definition of Manufacturing Suite shall include the Phase I Filling Space. 
 1.38
“Materials” means all API, excipients and processing aids, and processing, filling and packaging components, used in connection with the Manufacture of the Product and listed in Schedule 1.62 of the Manufacturing and Supply
Agreement, as amended prior to Product launch, based on the Parties’ most recent usage experience rate, and to reflect changes to the Specifications. 

1.39 “NDA” means the new drug application for a product, including the Product, requesting permission to place a drug on the
market in accordance with 21 C.F.R. Part 314, and all supplements filed pursuant to the requirements of the FDA, including all documents, data, and other information filed concerning such product that are necessary for FDA approval to market such
product in the Territory. 
 1.40 “NDC” means “national drug code,” a unique three-segment number, which is a
universal product identifier for human drugs. 
 1.41 “Party” or “Parties” has the meaning set forth in
the Preamble. 

  
 4 

 1.42 “Patheon” has the meaning set forth in the Preamble. 

1.43 “Patheon Indemnified Parties” has the meaning set forth in Section 7.1. 

1.44 “Patheon Manufacturing Equipment” has the meaning set forth in Exhibit 2.1-F. 

1.45 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture, or other similar entity or organization, including a government or political subdivision, department, or agency of a
government. 
 1.46 Not used. 

1.47 “Product” has the meaning set forth in the Recitals hereto, in finished, unpackaged form, according to the
Specifications. 
 1.48 “Project Manager” has the meaning set forth in Section 2.7(c). 

1.49 “Proprietary Information” has the meaning given in the Manufacturing and Supply Agreement. 

1.50 “Quality Agreement” has the meaning set forth in Section 3.1 of the Manufacturing and Supply Agreement. 

1.51 “Regulatory Approval” means any and all approvals (including pricing and reimbursement approvals), licenses,
registrations, or authorizations of any Regulatory Authority necessary to Exploit the Product in any country in the Territory, including any (a) approval of a Product, Marketing Authorization and supplements and amendments thereto;
(b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto); (c) labelling approval; and (d) technical, medical, and scientific licenses. 

1.52 “Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial, or local
regulatory agencies, departments, bureaus, commissions, councils, or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Product in the Territory. 

1.53 “Remediation Period” has the meaning set forth in Section 8.5. 

1.54 “Required Manufacturing Changes” has the meaning set forth in Exhibit 2.1-F. 

1.55 “Services” means the (a) Manufacturing Services performed by Patheon pursuant to the Manufacturing and Supply
Agreement; and (b) the Transfer Services performed by Patheon under this Agreement. 
 1.56 “Specifications” means the
specifications for each presentation of Product (i.e., the dosage forms in Schedule 1.82 of the Manufacturing and Supply Agreement) given by 

  
 5 

 
Flexion to Patheon relating to the specifications of the Materials; the manufacturing specifications, directions and processes; the storage requirements; all environmental, health and safety
information for the Product including material safety data sheets and the finished Product specifications, specifications for bulk and primary packaging and shipping requirements for the Product, as amended, modified, or supplemented from time to
time. 
 1.57 “Steering Committee” has the meaning set forth in Section 2.7(e). 

1.58 “Taxes” means all forms of taxation and statutory, governmental, state, federal, provincial, local, government or
municipal charges, duties, imposts, contributions, levies, withholding or liabilities wherever chargeable and whether of the United Kingdom or any other jurisdiction (including for the avoidance of doubt, national insurance contributions in the
United Kingdom) and any penalty, fine, surcharge, interest, charge, charges or costs thereto. 
 1.59 “Term” has the
meaning set forth in Section 8.1. 
 1.60 “Territory” means [...***...] and other territories agreed by the
Parties pursuant to Section 2.2(h) of the Manufacturing and Supply Agreement from time to time. 
 1.61 “Third Party”
means a Person who is neither a Party nor an Affiliate of a Party. 
 1.62 “Third Party Losses” means Losses incurred as a
result of claims brought by Third Parties. 
 1.63 “Timeline” has the meaning set forth in Section 2.1. 

1.64 “Transfer Services” means the services rendered under this Agreement, as described in Section 2.1 and in the
Exhibits attached to this Agreement, based on the Key Technical Assumptions stated therein. 
 1.65 “VAT” has the meaning
set forth in Section 9.15(c). 

  
  

***Confidential Treatment Requested 
  

6 

 ARTICLE 2 

TRANSFER SERVICES 

2.1 Description of Transfer Services. Patheon will (a) provide engineering and construction services, directly or using third
parties (pursuant to Section 9.8 hereto), to construct the Manufacturing Suite in accordance with the engineering approach and the footprints set forth in Exhibit 2.1-A of this Agreement, as it may be amended by mutual written agreement
of the Parties, and the projected capital requirements set forth in Exhibit 2.1-B, (b) procure and/or validate the Equipment necessary to Manufacture the Product in accordance with Exhibit 2.1-F and perform the Transfer Services
set forth in Exhibit 2.1-C, and (c) provide other services set forth in Exhibit 2.1-D in order to validate and implement Flexion’s Manufacturing Process for the Product in compliance with the Quality Agreement, GMP, all other
Applicable Law and the Specifications and register the Facility to Manufacture the Product (collectively, the “Transfer Services”). Patheon will perform the Transfer Services, (i) to facilitate the Regulatory Approval of the
Manufacturing Suite as the manufacturing, testing, and packaging sites for the Product, (ii) so that the Product is Manufactured and tested using Flexion’s Manufacturing Process including testing and releasing (pursuant to the terms of the
Quality Agreement) all Materials according to the Specifications and test methods, including the Specifications set forth in the NDA when approved. Patheon will use its commercially reasonable efforts to complete the Transfer Services in a timely
fashion in accordance with the schedule set forth in Exhibit 2.1-E (the “Timeline”). The Parties will cooperate with one another in the performance of this Agreement in good faith. 

2.2 Payments for Transfer Services. The Parties acknowledge and agree that Patheon’s consideration for the Transfer Services
performed hereunder is (a) the payment of the Base Fees, as set forth in Schedule 2.1(a) of the Manufacturing and Supply Agreement, (b) the payments associated with the Equipment, Manufacturing Suite construction and related process and
support and validation services, each in accordance with the capital requirements set forth in Exhibit 2.1-B (together, the “Capital Expenditures”); (c) charges for Bill Back Items; and (d) charges for Additional Services.
All payments from Flexion to Patheon hereunder shall be in British Pounds (GBP) and will be due and payable in accordance with the invoicing procedures set forth in ARTICLE IV of the Manufacturing and Supply Agreement. All invoices from Patheon to
Flexion for Capital Expenditures shall include all (if any) applicable invoices from vendors for the supply, transportation, installation, and commissioning of the Equipment that pertain to the Transfer Services invoiced by Patheon. Flexion
acknowledges that the amounts of Capital Expenditures are estimates and are subject to review once manufacturing details and process specification requirements have been confirmed, any necessary machine trials performed and upon receipt of formal
quotations from the equipment suppliers; provided however that, in no event shall the Capital Expenditures exceed the amount set forth in Exhibit 2.1-B by more than [...***...] percent ([...***...]%) unless otherwise mutually
agreed by the Parties in writing. 
 2.3 Modifications. The Parties may modify and agree upon the definitive engineering approach,
footprint of the Manufacturing Suite, or the Timeline, taking into account parameters such as the exact design of the space, space classifications, code requirements, Equipment, 

  
  

***Confidential Treatment Requested 
  

7 

 
materials, personnel, waste stream process flows, equipment sizing and utility requirements. Any such modifications shall be discussed by the Parties and agreed to in writing including as to any
consequential fees and costs or savings relating thereto, duly executed by the Parties. 
 2.4 Flexion’s Responsibilities. 

(a) To assist Patheon in its performance of the Transfer Services under this Agreement, Flexion shall (i) at its expense provide Patheon
in a timely fashion with relevant information, documentation, and data relating to (1) Flexion’s Manufacturing Process, (2) the Equipment necessary to Manufacture the Product in accordance with Flexion’s Manufacturing Process,
and (3) Product safety and information, documentation, and data, including any applicable NDA numbers, NDC codes, “CMC” sections of NDAs, validation protocols, validation reports, method validation protocols, method validation
reports, and other documents necessary or reasonably requested by Patheon for Patheon to Manufacture the Product, provide the Transfer Services or otherwise necessary for Patheon’s performance hereunder, and (ii) provide Flexion-Supplied
Materials pursuant to Section 2.10. If requested by Patheon to provide support or information, Flexion shall use commercially reasonable efforts to provide such reasonable and necessary support or information in order to enable Patheon to
perform the Transfer Services under this Agreement as soon as reasonably possible and in any event within [...***...] business days of Patheon’s request (or will provide an explanation of the legitimate reason for any delay and a
projected date by which such support or information will be provided). In the event Flexion is to review or approve any information, documentation, data, or samples prepared or supplied by or on behalf of Patheon, it will complete such review and
approval process as soon as reasonably possible and in any event within [...***...] business days of Patheon’s request. 
 (b) It
is understood and acknowledged by the Parties that Flexion will retain ownership of the IND and NDA to the Product, and any supplements thereto, and is responsible for the NDA submission documents and all correspondence with the FDA and other
competent Regulatory Authority concerning the Product, other than submission documents and correspondence associated with GMP inspections of the Facility; provided, however, that Section 2.9 of this Agreement and Sections 3.6 and 5.1 of the
Manufacturing and Supply Agreement will govern the ownership of the intellectual property rights described or disclosed in such NDA and supplements. 

(c) Flexion shall have the sole responsibility for the filing of all documents with all applicable Regulatory Authorities, and to take any
other actions that may be required for the receipt of Regulatory Approval for the development or commercial manufacture of the Product (other than the licences, registrations and Regulatory Authority approvals to be obtained by Patheon pursuant to
Section 3.3(b) of the Manufacturing and Supply Agreement). Flexion will, at its expense and in cooperation with Patheon, use commercially reasonable efforts to diligently and proactively pursue Regulatory Approval for Patheon’s Manufacture
of the Product at the Facility in a timely fashion in accordance with the Timeline. Without limiting such obligation, Flexion shall be responsible for filing the NDA submission documents, drug listing the Product,

  
  

***Confidential Treatment Requested 
  

8 

 
and completing correspondence with the FDA concerning the Product. All documentation and data provided by Patheon in support of the NDA filing shall be accurate and true and will reflect the
current processes and procedures in place at Patheon. Flexion shall provide Patheon with a copy of any Regulatory Approval relevant to this Agreement on request including any Regulatory Approval required for the storage, receipt or distribution of
the Product by Flexion or its designee. 
 (d) Where documents or data generated by Patheon in relation to the Transfer Services are to be
filed by Flexion with any Regulatory Authority and such filing includes data or information pertaining to a Patheon Regulatory Obligation within the meaning of Section 3.15 of the Manufacturing and Supply Agreement, prior to filing any such
documents and data with the Regulatory Authority, Flexion shall provide Patheon with a copy of the documents incorporating such data so as to give Patheon the opportunity to review the accuracy of such documents as it relates to the Patheon
Regulatory Obligation in accordance with the review and comment procedures set forth in Section 3.15 of the Manufacturing and Supply Agreement (including the process for resolution of inaccuracies set forth in Section 3.15(c) thereto).
Notwithstanding anything in Section 3.15 of the Manufacturing and Supply Agreement to the contrary: (i) at least [...***...] calendar days prior to filing with the Regulatory Authority any documentation which is or is equivalent to
the Quality document portion (Drug Product section) of the U.S. Investigational New Drug application, the EU Clinical Trial application and Investigational Medicinal Product Dossier, the Common Technical Document module 3 (Drug Product section) of
the US New Drug Application, U.S. Biological License Application, or the EU Marketing Authorization Application, as the case may be, Flexion shall provide Patheon with a copy of the Initial Draft (as defined in the Manufacturing and Supply
Agreement) of such portion so as to permit Patheon to verify that the Initial Draft accurately describes the development and validation work Patheon has performed and the manufacturing and control processes that Patheon will perform pursuant to this
Agreement; (ii) Patheon shall provide comments regarding such Initial Draft no later than [...***...] days prior to the required filing date with the applicable Regulatory Authority (including notifying Flexion of any identified
inaccuracies); and (iii) Flexion shall deliver a copy of the final version of the filing promptly after the required filing date. 

2.5 Patheon’s Responsibilities. Patheon will, at its expense, in consideration for the payments and reimbursements set forth in
Section 2.2, provide the Transfer Services and use its commercially reasonable efforts to complete the Transfer Services in a timely fashion in accordance with the Timeline. Patheon will provide to Flexion all data and documentation necessary
or reasonably useful to support Flexion’s submissions to the FDA, or any responses to questions raised by the FDA with respect to those Transfer Services, that are necessary or reasonably useful for Regulatory Approval of the Facility as the
manufacturing, testing, and packaging site for the Product. 
 2.6 Equipment. Patheon, acting as Flexion’s agent, shall purchase
the Flexion Manufacturing Equipment on Flexion’s behalf. Title to all Flexion Manufacturing Equipment will be held by Flexion. The Parties shall procure, supply, install, commission and validate the

  
  

***Confidential Treatment Requested 
  

9 

 
Equipment in compliance with (a) Exhibit 2.1-F; (b) the capital requirements set forth in Exhibit 2.1-B and (c) the “Qualification and Validation” process
set forth in Exhibit 2.1-C. Patheon is authorized to use the Flexion Manufacturing Equipment pursuant to Exhibit 2.1-F solely for the purposes of performing the Transfer Services and for the Manufacturing Services as set forth in
the Manufacturing and Supply Agreement. 
 2.7 Flexion On Site Representatives; Reporting of Results; Project Managers; Steering
Committee. 
 (a) Flexion shall have the right at all times throughout the Term to have [...***...] representatives (or other
number as reasonably requested by Flexion after discussion by the members of the Steering Committee) (each, a “Flexion On Site Representative”) present in that portion of the Facility that is being constructed or used to Manufacture
the Product or store Materials, to observe the procedures and processes used to Manufacture the Product or to perform the activities associated with the transfer of Flexion’s Technology hereunder. The Flexion On Site Representatives shall have
full access to the Manufacturing Suite and to the non-financial records that relate to the Product, and all records pertaining to any Materials and to Third Party invoices specifically invoiced by Patheon to Flexion as a Capital Expenditure or Bill
Back Item. For the avoidance of doubt, the term “non-financial records” as used in this Agreement does not include the Reports (defined in Section 3.11 of the Manufacturing and Supply Agreement). Patheon shall provide reasonable
(semi-permanent) on-site accommodations at the Facility for the Flexion On Site Representatives (e.g., office space). Flexion On Site Representatives shall be appropriately trained by Flexion (e.g. GMP training) and shall observe at all
times Patheon’s policies and procedures (as amended from time to time) as they pertain to the Facility, including policies relating to health and safety and compliance with GMP; provided that Flexion is given notice of such policies and given a
reasonable period of time to review and implement such policies. Flexion will comply with all reasonable directions of Patheon in relation to the same. Patheon may refuse or limit in its sole discretion at any time admission to the Facility by any
Flexion On Site Representative who fails to observe such policies or comply with such reasonable directions. For the avoidance of doubt, Flexion On Site Representatives shall have (i) no management authority over any Patheon employee and
(ii) no authority to conclude contracts on behalf of Flexion. 
 (b) Patheon will respond to Flexion’s inquiries regarding the
status of the Transfer Services on an ongoing basis, and Patheon will endeavor to keep Flexion informed of interim results of the Transfer Services. Patheon will provide copies of all analytical, cleaning, and process validation protocols, data
summaries, reports and all batch records, test methods, and specifications for Flexion’s review, comment, and approval prior to implementation and execution. Once such protocols, data summaries, reports, records, methods, and specifications
have been approved and executed, Patheon will provide copies to Flexion. Patheon will provide Flexion with information relating to the Equipment to be used in connection with the Manufacture of the Product, which Equipment will be subject to
Flexion’s review and approval (not to be unreasonably withheld or delayed). Within five (5) business days after Flexion’s 

  
  

***Confidential Treatment Requested 
  

10 

 
request, Patheon will provide to Flexion documentation that summarizes the implementation efforts of the Transfer Services at the Facility. 

(c) Patheon and Flexion will each appoint a project manager (each, a “Project Manager” and, together, the “Project
Managers”), who will meet as needed to resolve any issues or problems associated with the Transfer Services. Flexion’s Project Manager may be one of the Flexion On Site Representatives. Flexion reserves the right to request replacement
of any personnel assigned by Patheon to perform the Transfer Services hereunder. If Patheon disagrees with such request and the Parties cannot reach resolution on Flexion’s request for replacement, such request will be discussed by the Steering
Committee pursuant to the procedures set forth in Exhibit 2.7 hereto. 
 (d) Patheon shall ensure that sufficient numbers of
adequately educated and experienced staff are retained at the Facility in order to provide the Transfer Services. Patheon shall perform the Transfer Services under the direction of key personnel of Patheon to a project for the duration of the
project (“Key Personnel”). Key Personnel include the Project Manager, Operational Manager, Quality Manager or other personnel reasonably agreed-to by the Parties. Patheon shall provide information on the qualifications and
background of all proposed Key Personnel prior to such Key Personnel’s commencement of activities under this Agreement on Patheon’s behalf. Patheon will not remove Key Personnel without Flexion’s prior written consent (not to be
unreasonably withheld, conditioned or delayed) except in the event of such Key Personnel’s promotion, resignation, incapacity or death, or termination for cause. Patheon will use commercially reasonable efforts to minimize turnover in Key
Personnel, and will provide [...***...] business days’ notice to Flexion, whenever practical, of any changes to the Key Personnel, at which point, both Parties shall discuss and reasonable agree on a suitable replacement. 

(e) The Parties desire to establish a steering committee (the “Steering Committee”) as described in Exhibit 2.7. 

2.8 Dispute Resolution. 

(a) The Parties recognize that disputes may arise from time to time during the term of this Agreement that relate to whether either Party has
fulfilled its obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes arising under this Agreement in an expedient manner by mutual cooperation. To accomplish this objective,
the Parties agree to follow the procedures set forth in this Section 2.8 if and when a dispute arises under this Agreement. 
 (b)
Unless otherwise specifically recited in the Agreement, disputes between the Parties under this Agreement will be first referred to the Project Manager of each Party as soon as reasonably possible after such dispute has arisen. If the Project
Managers are unable to resolve such a dispute within [...***...] days of being requested by a Party to resolve such dispute, either Party may, by written notice to the other, have such dispute referred to the

  
  

***Confidential Treatment Requested 
  

11 

 
Steering Committee. If the Steering Committee is unable to resolve such a dispute within [...***...] day of being requested by a Party to resolve such dispute, either Party may, by written
notice to the other, have such dispute referred to the [...***...] of each Party for attempted resolution by negotiations within [...***...] days after such notice received. 

2.9 Ownership. The Parties’ intellectual property ownership rights relating to the subject matter of this Agreement shall be
governed by ARTICLE V of the Manufacturing and Supply Agreement. 
 2.10 Materials. Patheon will purchase all Patheon-Supplied
Materials (as defined in the Manufacturing and Supply Agreement) for the Transfer Services as set forth in Schedule 1.62 of the Manufacturing and Supply Agreement. Flexion shall purchase all Flexion-Supplied Materials (as defined in the
Manufacturing and Supply Agreement) for the Transfer Services and ship such Flexion-Supplied Materials to Patheon in accordance with this Section 2.10 (except as otherwise mutually agreed to by the Parties in writing, in which case such
Materials shall be considered Bill Back Items hereunder). All shipments from Flexion to Patheon will be made DDP (Incoterms 2010) the Facility unless otherwise agreed. All shipments of Flexion-Supplied Materials, if required, will be accompanied by
Certificate(s) of Analysis from the Material manufacturer or Flexion, confirming its compliance with the Material’s specifications. Flexion will obtain the proper release of the Flexion-Supplied Materials from the applicable customs agency and
Regulatory Authority. Flexion or Flexion’s designated broker will be the “Importer of Record” for Flexion-Supplied Materials imported to the Facility. Flexion-Supplied Materials will be held by Patheon on behalf of Flexion as set
forth in this Agreement. Title to Flexion-supplied Materials will at all times remain the property of Flexion or a Flexion Affiliate. Any Flexion-Supplied Materials received by Patheon will only be used by Patheon to perform the Transfer Services or
associated activities necessary to perform the Transfer Services (e.g., media fills or validation runs). 
 2.11 Bill Back Items.
Bill Back Items will be charged to Flexion at Patheon’s cost plus a [...***...]% handling fee. Patheon shall invoice Flexion monthly for any Bill Back Items used in connection with the Transfer Services during the preceding month in
accordance with ARTICLE IV of the Manufacturing and Supply Agreement. Patheon may only invoice Bill Back Items that have been quoted to and approved in writing by Flexion’s Project Manager, or otherwise mutually agreed to by the parties in
advance. 
 2.11A Additional Services. If Flexion is interested in having Patheon perform Additional Services, Flexion will provide
Patheon with a written request containing sufficient detail to enable Patheon to provide Flexion with a quote and proposal to provide such Additional Services. Patheon may only invoice for Additional Services that have been quoted to and approved in
writing by Flexion’s Project Manager and that have been agreed in writing by the Parties in a Change of Scope Agreement. Patheon shall invoice Flexion monthly for any Additional Services performed by Patheon during the preceding month in
accordance with ARTICLE IV of the Manufacturing and Supply Agreement. 

  
  

***Confidential Treatment Requested 
  

12 

 2.12 Storage. Patheon will provide storage capacity to support storage of the required
quantity of Materials necessary for Transfer Services which will be governed by Section 2.2(e) of the Manufacturing and Supply Agreement. 

2.13 Shipping. Except to the extent set forth otherwise in this Agreement, any shipment from Patheon to Flexion, whether of Product,
Materials or otherwise, shall be made pursuant to Section 2.3(e) of the Manufacturing and Supply Agreement. 
 2.14 Changes in
Applicable Law. Should during the Term of this Agreement, a change or changes in Applicable Law lead to Patheon (a) providing services not originally contemplated by Patheon, or (b) incurring increased costs in order to comply with
said change or changes, any such services or costs (to the extent pertaining to the Product or related to Flexion’s Manufacturing Process or the Flexion Manufacturing Equipment) shall constitute an Additional Service subject to mutual written
agreement of the Parties; provided that, if such services or costs relate generically to the entire Facility then such costs to Flexion shall be prorated as applicable. 

2.15 Base Fees. Patheon will invoice Flexion monthly in advance for the Base Fees, and such Base Fees will be due and payable, in
accordance with the provisions and invoicing procedures set forth in ARTICLE IV of the Manufacturing and Supply Agreement. 
 ARTICLE 3
 
 CONFIDENTIALITY 

3.1 Confidentiality Obligations. The Parties agree that the terms of ARTICLE VII of the Manufacturing and Supply Agreement shall govern
the confidentiality obligations of the Parties and are incorporated herein by this reference. 
 ARTICLE 4  

FLEXION’S REPRESENTATIONS, 

WARRANTIES, AND COVENANTS 

4.1 Commercially Reasonable Efforts. Except where specifically stated to the contrary in this Agreement otherwise, Flexion will use its
commercially reasonable efforts to perform Flexion’s obligations hereunder. 
 4.2 Additional Representations, Warranties, and
Covenants of Flexion. Flexion warrants, represents, and covenants that as of the Effective Date the warranties, representations and covenants set out in Sections 6.4(a) of the Manufacturing and Supply Agreement shall apply to the
performance of the Transfer Services. 

  
 13 

 ARTICLE 5 

PATHEON’S REPRESENTATIONS, 

WARRANTIES, AND COVENANTS 

Patheon represents, warrants, and covenants to Flexion as follows: 

5.1 Commercially Reasonable Efforts. Except where specifically stated to the contrary in this Agreement otherwise, Patheon will use its
commercially reasonable efforts to perform the Transfer Services in accordance with the agreed upon Timeline. In the event Patheon is not able to meet the Timeline, Patheon will provide written notice to Flexion of such inability as soon as
practical, but in any event within [...***...] of discovering such inability. 
 5.2 Qualified Personnel and Transfer Services.
Patheon will engage and employ professionally qualified personnel to perform the Transfer Services contemplated hereunder. Patheon represents and warrants that there is no claim, suit, proceeding, or other investigation issued on Patheon, or to the
knowledge of Patheon (after due inquiry), pending or threatened against Patheon, which is likely to prevent or materially adversely affect the rights and interests of Flexion hereunder or keep Patheon from performing its obligations hereunder. 

5.3 Additional Representations, Warranties, and Covenants of Patheon. Patheon warrants, represents, and covenants that: 

(a) (i) it has facilities, personnel, experience, and expertise sufficient in quality and quantity to perform the obligations hereunder,
(ii) it shall so perform in conformity with GMPs where applicable, and (iii) its management shall establish, and Patheon shall observe and comply with, appropriate quality assurance, quality controls, and review procedures for
implementation of the Transfer Services; 
 (b) it has at the Effective Date and shall during the Term observe and comply with, at (subject
to Section 2.14) its sole cost and expense, all Applicable Laws now in force or that may hereafter be in force, including federal, state, and local laws, orders, regulations, rules, customs, and ordinances now in force or that may hereafter be
in force pertaining to Patheon’s performance of the Transfer Services and the Facility and including, without limitation, (i) labor laws, orders, regulations, rules, customs, and ordinances and (ii) those of the FDA pertaining to
Patheon’s performance of the Transfer Services and the Facility, and any laws, orders, regulations, rules, or ordinances issued in addition to, as a supplement to or as a replacement of Applicable Laws. 

(c) none of it, its Affiliates, nor any Person under its direction or control has ever been, nor will it engage suppliers which have to its
actual knowledge, after due inquiry, been, (i) debarred or convicted of a crime for which a person can be debarred, under Section 335(a) or 335(b) of the Act, or any equivalent Applicable Law of the country of Manufacture,
(ii) threatened to be debarred under the Act or any equivalent Applicable Law of the country of Manufacture or (iii) indicted for a crime or otherwise (to its actual knowledge after due inquiry) 

  
  

***Confidential Treatment Requested 
  

14 

 
engaged in conduct for which a person can be debarred under the FDA or any equivalent Applicable Law of the country of Manufacture, and Patheon agrees that it will, within [...***...],
notify Flexion in the event it receives notification of any such debarment, conviction, threat or indictment. Should Patheon become aware of any actual or suspected noncompliance with the foregoing, Patheon will notify Flexion in writing of such
issue within [...***...]. For the purpose of this Section 5.3, suppliers and subcontractors engaged by Patheon to undertake the Manufacture of the Product shall be deemed to be under Patheon’s direction or control; 

(d) none of it, its Affiliates, nor any Person under its direction or control is currently excluded from a federal or state health care
program under Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 or any equivalent Applicable Law of the country of Manufacture, as may be amended or supplemented; 

(e) none of it, its Affiliates, nor any Person under its direction or control is otherwise currently excluded from contracting with the U.S.
federal government or the government of the country of Manufacture; 
 (f) none of it, its Affiliates, nor any Person under its direction or
control is otherwise currently excluded, suspended, or debarred from any U.S. or foreign governmental program; 
 (g) it shall immediately
notify Flexion if, at any time during the Term, Patheon, its Affiliates, or any Person under its direction or control is convicted of an offense that would subject it or Flexion to exclusion, suspension, or debarment from any U.S. or foreign
governmental program; and 
 (h) it will not enter into any agreement or arrangement with any other Person that would prevent its ability to
perform its obligations hereunder. 
 5.4 Legal Compliance. Section 6.6 of the Manufacturing and Supply Agreement shall apply to
this Agreement and any violation thereof by Patheon or its employees, agents, or contractors in the performance of this Agreement shall constitute a material default for the purpose of Section 8.5 of this Agreement. 

5.5 Disclaimer. THE FOREGOING EXPRESS WARRANTIES AND THOSE IN ARTICLE 4 and ARTICLE 6 ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT, AND ALL OTHER WARRANTIES ARE HEREBY DISCLAIMED AND EXCLUDED BY EACH PARTY. 

  
  

***Confidential Treatment Requested 
  

15 

 ARTICLE 6  

GENERAL REPRESENTATION AND WARRANTIES 

Each Party represents, warrants, and covenants to the other as follows: 

6.1 Power and Authorization. Such Party (a) is duly formed and in good standing under the laws of the jurisdiction of its
formation, (b) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder, and (c) has taken all necessary action on its part required to authorize the execution and delivery of
this Agreement and the performance of its obligations hereunder. 
 6.2 Enforceability. This Agreement has been duly executed and
delivered on behalf of such Party and constitutes a legal, valid, and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other similar laws of general
application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity. Except for the
FDA’s approval of Patheon’s manufacturing, testing, and packaging for the Product from the Manufacturing Suite, all necessary consents, approvals, and authorizations of all Regulatory Authorities, other governmental authorities, and other
Persons required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

6.3 No Conflict. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder
(a) do not and will not conflict with or violate any requirement of Applicable Law or any provision of the articles of incorporation, bylaws, limited partnership agreement, or other constituent document of such Party and (b) do not and
will not conflict with, violate, or breach, or constitute a default or require any consent under, any contractual obligation or court or administrative order by which such Party is bound. 

6.4 Compliance with Applicable Law. Each Party and its Affiliates, and their respective representatives, shall comply with all
Applicable Laws in the performance of their obligations under this Agreement. Without limiting the foregoing, each Party and its Affiliates, and their respective representatives, shall comply with export control laws and regulations of the country
of Manufacture and of the United States. Neither Party nor its Affiliates (or representatives) shall, directly or indirectly, without prior U.S. government authorization, export, re-export, or transfer the Product to any country subject to a U.S.
trade embargo, to any resident or national of any country subject to a U.S. trade embargo, or to any person or entity listed on the “Entity List” or “Denied Persons List” maintained by the U.S. Department of Commerce or the list
of “Specifically Designated Nationals and Blocked Persons” maintained by the U.S. Department of Treasury. In so far as the same applies to a Party or its Affiliates, each Party and its Affiliates and respective representatives shall comply
with the requirements of the Foreign Corrupt Practices Act of 1977 (15 U.S.C. § 78dd-1, et seq.). 

  
 16 

 ARTICLE 7 

INDEMNIFICATION 

7.1 Indemnification by Flexion. Flexion will indemnify Patheon, its Affiliates, and their respective directors, officers, employees,
and agents (the “Patheon Indemnified Parties”), and defend and save each of them harmless from and against any and all (i) Third Party Loss incurred by any of them in connection with, arising from, or occurring as a result of
(a) any claim of personal injury or property damage to the extent that the injury or damage is the result of or arises other than from a breach of this Agreement by Patheon, (b) a claim that the Transfer Services performed by Patheon
hereunder, in accordance with the terms and conditions of this Agreement, infringes or misappropriates a patent or any other intellectual property rights, if it is a claim related to the use of Flexion Manufacturing Equipment, Existing Flexion
Intellectual Property (as defined in the Manufacturing and Supply Agreement), Flexion Improvements (as defined in the Manufacturing and Supply Agreement) or the Manufacturing Process or the Product, (c) any negligence or willful misconduct by
Flexion or any of its Affiliates, or (d) any breach by Flexion of any of its obligations or any inaccuracy of any of Flexion’s warranties under this Agreement, or (ii) any Loss incurred by any of them as a direct result of and to the
extent of the negligence or willful misconduct of the Flexion On Site Representatives at the Facility, except, in each case, for those Losses for which Patheon has an obligation to indemnify the Flexion Indemnified Parties pursuant to
Section 7.2 below, as to which Losses each Party shall indemnify the other to the extent of their respective liability for such Losses; and provided, however, that Flexion will not be required to indemnify the Patheon Indemnified Parties with
respect to any such Loss hereunder to the extent the same is caused by any breach of contract, negligent act or omission, or intentional misconduct by Patheon or any or its Affiliates. For the avoidance of doubt, the parties acknowledge that Patheon
has not and will not conduct any freedom to operate searches in relation to the Product and/or Flexion’s Manufacturing Process nor reviewed any third party patents in relation thereto and that Patheon’s failure or omission to do so will
not be considered negligence for the purposes of excluding or limiting a claim under this indemnity. 
 7.2 Indemnification by
Patheon. Patheon will indemnify Flexion, its Affiliates, and their respective directors, officers, employees, and agents (the “Flexion Indemnified Parties”), and defend and save each of them harmless from and against any and all
Third Party Loss incurred by any of them in connection with, arising from, or occurring as a result of (a) any claim of personal injury or property damage to the extent that the injury or damage is the result of a failure by Patheon to perform
the Transfer Services in accordance with the terms of this Agreement; (b) a claim that any Existing Patheon Intellectual Property (as defined in the Manufacturing and Supply Agreement) or other intellectual property of Patheon employed by
Patheon in providing the Transfer Services infringes or misappropriates a United States patent or any other intellectual property rights except to the extent such claim is based on the use of Existing Flexion Intellectual Property, Flexion
Improvements, the Manufacturing Process or the Product in accordance with the terms and conditions of this Agreement, (c) any claim of personal injury or property damage to the extent that the injury or damage is the result of any negligence or
willful misconduct by Patheon or any of its Affiliates, or (d) any claim of personal injury or property damage to the extent that the injury or damage is the result of any breach by Patheon of any of its obligations or any inaccuracy of any of
Patheon’s warranties under this Agreement; except, in each case, for those Losses for which Flexion has an obligation to indemnify the 

  
 17 

 
Patheon Indemnified Parties pursuant to Section 7.1 above, as to which Losses each Party shall indemnify the other to the extent of their respective liability for such Losses; and provided,
however, that Patheon will not be required to indemnify the Flexion Indemnified Parties with respect to any such Loss hereunder to the extent the same is caused by any breach of contract, negligent act or omission, or intentional misconduct by
Flexion or any or its Affiliates. 
 7.3 Indemnification Procedures. 

(a) Notice of Claim. The indemnified Party (the “Indemnified Party”) shall give the indemnifying Party (the
“Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Loss, action, or discovery of facts upon which such Indemnified Party intends to base a request for indemnification under
Section 7.1 or 7.2 (a “Claim”), but in no event shall the Indemnifying Party be liable for any Loss that results from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the Claim
and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in
respect of any Loss upon which it intends to seek indemnification. 
 (b) Control of Defense. At its option, the Indemnifying Party
may assume the defense of any Claims by giving written notice to the Indemnified Party within [...***...] days after the Indemnifying Party’s receipt of an Indemnification Claim Notice; provided that the assumption of the defense of a
Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses
it may assert against any Indemnified Party’s Claim. Upon assuming the defense of a Claim, the Indemnifying Party may appoint as lead counsel in the defense of such Claim any legal counsel selected by the Indemnifying Party. In the event the
Indemnifying Party assumes the defense of a Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnified Party in connection with the Claim.
Subject to clause (c) below, if the Indemnifying Party assumes the defense of a Claim, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with
the analysis, defense, or settlement of such Claim. In the event that it is ultimately determined that the Indemnifying Party is not obliged to indemnify, defend, or hold harmless an Indemnified Party from and against any Claim, the Indemnified
Party shall reimburse the Indemnifying Party for any and all costs and expenses (including reasonable attorneys’ fees and costs of suit) and any Loss incurred by the Indemnifying Party in its defense of such Claim. 

(c) Right to Participate in Defense. Without limiting Section 7.3(b), any Indemnified Party shall be entitled to participate in,
but not control, the defense of a Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified Party’s own expense unless (i) the employment thereof has been specifically
authorized by the Indemnifying Party in writing, (ii) the Indemnifying Party has failed to assume 

  
  

***Confidential Treatment Requested 
  

18 

 
the defense and employ counsel in accordance with Section 7.3(b) (in which case the Indemnified Party shall control the defense), or (iii) the interests of the Indemnified Party and the
Indemnifying Party with respect to such Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules, or equitable principles. 

(d) Settlement. With respect to any Loss relating solely to the payment of money damages in connection with a Claim and that will not
result in the Indemnified Party’s becoming subject to injunctive or other relief or otherwise adversely affect the business or reputation of the Indemnified Party in any manner, and as to which the Indemnifying Party shall have acknowledged in
writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement, or otherwise dispose of such Loss, on such terms as the
Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Claims, where the Indemnifying Party has assumed the defense of the Claim in accordance with Section 7.3(b), the
Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement, or otherwise dispose of such Loss; provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be
unreasonably withheld or delayed). The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, agree to any settlement or acquiesce to any judgment with respect to a Claim that obligates the Indemnified Party to pay
any amount subject to indemnification by the Indemnifying Party or causes the Indemnified Party to admit to any civil or criminal liability. 

(e) Cooperation. If the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party shall cooperate in the
defense or prosecution thereof and shall, at the Indemnifying Party’s expense, furnish such records, information, and testimony, provide such witnesses, and attend such conferences, discovery proceedings, hearings, trials, and appeals as may be
reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of records and information that are reasonably
relevant to such Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party
for all its reasonable time and out-of-pocket expenses in connection therewith. 
 (f) Expenses. Except as provided above, the
reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Claim shall be reimbursed on a monthly basis in arrears by the Indemnifying Party, without prejudice
to the Indemnifying Party’s right to, contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obliged to indemnify the Indemnified Party. 

7.4 Limitation of Liability. 

(a) SUBJECT TO SECTION 7.4(b) BELOW, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR (I) ANY (DIRECT OR INDIRECT) LOSS OF PROFITS, OF
PRODUCTION, OF ANTICIPATED SAVINGS, OF BUSINESS, OF GOODWILL OR OF 

  
 19 

 
USE OF THE PRODUCT OR COSTS OF ANY SUBSTITUTE SERVICES OR (II) FOR ANY OTHER LIABILITY, DAMAGE, COST OR EXPENSE OF ANY KIND INCURRED BY THE OTHER PARTY OF AN INDIRECT OR CONSEQUENTIAL NATURE,
REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF THE DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE DAMAGES AVAILABLE FOR BREACHES OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 3. 

(b) Nothing in this Agreement is intended to limit either Party’s liability for: (i) death or personal injury caused by its
negligence; or (ii) fraud or fraudulent misrepresentation. 
 (c) If any part of the Transfer Services provided or procured by Patheon
is not materially performed in accordance with the terms of this Agreement, then Flexion’s sole remedy whether in contract, tort, equity or otherwise (in addition to those expressly set forth in ARTICLE 8) will be for Patheon to repeat that
part of the Transfer Service at Patheon’s cost (provided that where the Transfer Services to be repeated requires Flexion-Supplied Materials, Flexion will provide such Flexion-Supplied Materials and Patheon shall reimburse Flexion for the
actual costs for such Flexion-Supplied Materials, including associated shipment costs); provided that, (i) Patheon shall only be liable to reimburse the costs of any Flexion-Supplied Materials and associated shipment costs [...***...],
and (ii) Patheon’s aggregate liability in each calendar year (liability cap to be pro-rated for partial calendar years) to reimburse the costs of any Flexion-Supplied Materials shall not exceed [...***...]% of the [...***...]
received by Patheon in the [...***...] period prior to the month in which the underlying event occurred that gave rise to the liability (e.g. the date of the incident or manufacture) up to a maximum of £[...***...]. Patheon
shall not be liable to reimburse the cost of any Flexion-Supplied Materials under any other circumstances. 
 7.5 Insurance. During
the Term and for [...***...] thereafter, each Party shall procure and maintain at its own expense from a qualified and licensed insurer liability insurance or indemnity policies, in an amount not less than $[...***...] in the aggregate
with respect to public and products liability, subject to such deductible or self-retention limits as either Party in its business discretion may elect. Such policies shall insure against liability on the part of each Party and any of its
Affiliates, as their interests may appear, due to injury, disability, or death of any person or persons, or injury to property, arising from the distribution of the Products. Each Party will either (a) include the other Party and its officers,
employees and consultants as additional insureds on such policies, or (b) ensure that such policy contains an indemnity to principal clause. Promptly following the execution of this Agreement, each Party shall provide to the other a certificate
of insurance (i) summarizing the insurance coverage and (ii) identifying any exclusions. Each Party shall promptly notify the other of any material adverse alterations to the terms of this policy or decreases in the amounts for which
insurance is provided. 

  
  

***Confidential Treatment Requested 
  

20 

 ARTICLE 8  

TERM AND TERMINATION 

8.1 Term. This Agreement will remain in full force and effect unless and until it expires or is terminated in accordance with the
provisions of this ARTICLE 8 (the “Term”). 
 8.2 Expiration. This Agreement will expire upon completion of the
Transfer Services as described herein or until the Parties agree that the Transfer Services have been completed (the “Completion of the Tech Transfer”). 

8.3 Termination by Flexion. Flexion may terminate this Agreement in its entirety (a) prior to the FDA Approval Date by giving
Patheon ninety (90) days’ written notice for convenience, in which case, Section 8.11(f) shall apply, or (b) by giving Patheon thirty (30) days written notice if Patheon (due primarily to its acts or omissions) fails to
complete Manufacturing Suite construction by the date stated in the Timeline and due solely to such failure, Patheon has not Manufactured registration batches in the Manufacturing Suite by [...***...]. 

8.4 Termination by Mutual Agreement. This Agreement may be terminated at any time upon mutual written agreement between the Parties.

 8.5 Termination for Default. Each Party will have the right to terminate this Agreement at any time upon written notice to the
other Party, if such other Party (a) breaches any of the representations, warranties, covenants, or agreements set forth in this Agreement or (b) otherwise defaults in the performance of any of its duties or obligations under this
Agreement, which in either case has a material effect on the other Party, and which breach or default is not cured within ninety (90) days after written notice is given to the breaching Party specifying the breach or default
(“Remediation Period”). The aggrieved Party’s right to terminate this Agreement for a particular breach under this Section 8.5 may only be exercised for a period of one hundred and twenty (120) days following the
expiry of the Remediation Period (where the breach has not been remedied) and, if the termination right is not exercised during this period, then the aggrieved Party will be deemed to have waived its right to terminate this Agreement for such
breach. 
 8.6 Bankruptcy; Insolvency. To the extent permitted by law, each Party will have the right to terminate this Agreement
immediately upon notice to the other Party, if the other Party shall file in any court or agency, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for arrangement or for
the appointment of a receiver or trustee of the other Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary petition against it,
filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if the other Party shall make
an assignment for the benefit of its creditors. 

  
  

***Confidential Treatment Requested 
  

21 

 8.7 Cross Termination. Should either Flexion or Patheon exercise its right to terminate
this Agreement or the Manufacturing and Supply Agreement in its entirety (but not in the event of an expiration of this Agreement as set forth in Section 8.2) prior to the FDA Approval Date, then the Manufacturing and Supply Agreement, this
Agreement and the Quality Agreement will concurrently and automatically terminate. 
 8.8 No Release. Neither the termination nor
expiration of this Agreement will release or operate to discharge either Party from any liability or obligation that may have accrued prior to such termination or expiration, including any obligation to pay to the other Party any amounts accrued
under this Agreement with respect to the period prior to the effective date of such expiration or termination. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof will not limit
remedies that may otherwise be available in law or equity. 
 8.9 Obligations. Notwithstanding the giving of any notice of
termination pursuant to this ARTICLE 8, each Party will continue to fulfill its obligations under this Agreement at all times until the effective date of any such termination or expiration. 

8.10 Survival. The expiration or termination of this Agreement shall be without prejudice to any rights or obligations of the Parties
that may have accrued prior to such termination, and the provisions of Sections 2.2 (as it may relate to any unpaid amounts due and owing), 2.6 (as it may relate to the use to which Patheon may put the Flexion Manufacturing Equipment), 2.8, 2.9 and
ARTICLE 1, ARTICLE 3, ARTICLE 7, ARTICLE 8, and ARTICLE 9 shall survive the expiration or termination of this Agreement. 
 8.11 Rights
and Duties Upon Termination. 
 (a) Upon termination of this Agreement, Patheon will, as promptly as practicable, (i) cease work on
the Transfer Services, and (ii) make available for collection by Flexion, [...***...] (Incoterms 2010) the Facility, all Materials and results and information resulting from the Transfer Services (whether in written or electronic form)
that are then in Patheon’s or its subcontractors’ possession and that are the property of Flexion in accordance with Section 2.9 of this Agreement, including all Flexion Proprietary Information. Flexion shall return to Patheon all
Patheon Proprietary Information. 
 (b) Upon termination of this Agreement, Flexion will (i) pay all earned but unpaid fees and charges
for the Transfer Services, including Material Costs, Capital Expenditures, Bill Back Items, Additional Services, Base Fees (through the month of such termination) to reflect Transfer Services performed as of the date of such termination by Patheon;
and (ii) pay all due and outstanding invoices in accordance with ARTICLE IV of the Manufacturing and Supply Agreement, including those for Bill Back Items or Additional Services performed as of the date of such expiration and termination;
provided that, the Parties agree that if any fees or charges are duplicated under Section 8.3 of the Manufacturing and Supply Agreement, Flexion shall only be obligated to make such payment once. 

  
  

***Confidential Treatment Requested 
  

22 

 (c) Upon termination of this Agreement, Flexion will pay to Patheon all and any removal and Make
Good Costs associated with the removal of the Flexion Manufacturing Equipment from the Facility as agreed to in good faith by the Parties in writing. “Make Good Costs” means the reasonable costs required to repair the Facility and
return it to a clean, safe and useable area based on the repair of damage caused by the installation or removal of Flexion Manufacturing Equipment. 

(d) Upon termination of this Agreement prior to termination of the Manufacturing and Supply Agreement, Flexion will, as promptly as
practicable, pay to Patheon the Manufacturing Services Termination Costs pursuant to the provisions of Sections 8.3(f) and 8.3(g) of the Manufacturing and Supply Agreement to the extent applicable to this Agreement or the Transfer Services. 

(e) Upon termination of this Agreement, in the event that Patheon will not be Manufacturing the Product for Flexion pursuant to the
Manufacturing and Supply Agreement, Flexion shall remove all Flexion Manufacturing Equipment and Materials from the Facility within [...***...] days of said termination under all sections other than Section 8.5 and within
[...***...] days [...***...] of a termination by Flexion pursuant to Section 8.5 that is not reasonably disputed by Patheon, failing which Flexion will pay a fee equivalent to the aggregate monthly Base Fee for each month or part
month the Flexion Manufacturing Equipment or Materials remain at the Facility post-termination. 
 (f) Upon termination of this Agreement by
Flexion pursuant to Section 8.3(a), in addition to any other obligation of Flexion under Section 8.11, Flexion shall also pay Patheon compensation of £[...***...] British Pounds). The Parties confirm that this sum represents a
genuine pre-estimate of Patheon’s loss in such circumstances. 
 ARTICLE 9  

MISCELLANEOUS 
 9.1
Notices. Notwithstanding that advance notification of any notices or other communications may be given by electronic mail transmission, all notices or other communications that shall or may be given pursuant to this Agreement shall be in
writing (including by confirmed receipt electronic mail) and shall be deemed to be effective (a) when delivered if sent by registered or certified mail, return receipt requested, or (b) on the next business day, if sent by overnight
courier, (c) when sent if sent by electronic mail provided that receipt is confirmed, in each case to the Parties at the following addresses (or at such other addresses as shall be specified by like notice) with postage or delivery charges
prepaid. 
 If to Flexion: 

Flexion Therapeutics, Inc. 
 Attn:
Michael Clayman, MD 
 Telephone: [...***...] 

  
  

***Confidential Treatment Requested 
  

23 

 Email: [...***...] 

With a copy to: Legal 
 If to
Patheon: 
   Attention: 

Executive Director & General Manager 

Patheon UK Limited 
 Kingfisher
Drive, Covingham 
 Swindon, Wiltshire SN3 5BZ 

England 
 Email:
[...***...] 
   with copy to 

Legal Director. 
 9.2 Force
Majeure. Neither Party shall be liable for delay in delivery, performance or nonperformance, in whole or in part, nor shall the other Party have the right to terminate this Agreement except as otherwise specifically provided in this
Section 9.2 where such delay in delivery, performance or nonperformance results from acts beyond the reasonable control and without the fault or negligence of such Party including, but not limited to, the following conditions: fires, floods,
storms, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotion, or acts, omissions, or delays in acting by any governmental authority; provided that the Party
affected by such a condition shall, within five (5) days of its occurrence, give notice to the other Party stating the nature of the condition, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension
of performance shall be of no greater scope and no longer duration than is reasonably required, and the nonperforming Party shall use its commercially reasonable efforts to remedy its inability to perform; provided, however, that in the event the
suspension of performance continues for [...***...] days after the date of the occurrence, and such failure to perform would constitute a material breach of this Agreement in the absence of such force majeure event, the non-affected Party may
terminate this Agreement immediately by written notice to the affected Party. 
 9.3 Independent Contractor. The Parties to this
Agreement are independent contractors. Nothing contained in this Agreement will be construed to place the Parties in the relationship of employer and employee, partners, principal, and agent or a joint venture. Neither Party will have the power to
bind or obligate the other Party nor will either Party hold itself out as having such authority. 
 9.4 Waiver. Save where expressly
stated to the contrary in this Agreement, no waiver by either Party of any provision or breach of this Agreement will constitute a waiver by such 

  
  

***Confidential Treatment Requested 
  

24 

 
Party of any other provision or breach, and no such waiver will be effective unless made in writing and signed by an authorized representative of the Party against whom waiver is sought. No
course of conduct or dealing between the Parties will act as a modification or waiver of any provision of this Agreement. Either Party’s consent to or approval of any act of the other Party will not be deemed to render unnecessary the obtaining
of that Party’s consent to or approval of any subsequent act by the other Party. 
 9.5 Entire Agreement. This Agreement
(together with all Exhibits hereto, which are hereby incorporated by reference), the Manufacturing and Supply Agreement and the Quality Agreement, constitute the final, complete, and exclusive agreement between the Parties relating to the subject
matter hereof and supersede all prior conversations, understandings, promises, and agreements relating to the subject matter hereof, including without limitation that (i) certain Confidentiality Agreement dated September 22, 2014 between
Flexion and Patheon and the Letter Agreement between the Parties dated 1 May 2015, and (ii) that certain Patheon Partner External User Account/Access Form, Client Agreement and Authorization signed by Flexion on June 5, 2015. Neither
Party has relied upon any communication, representation, term, or promise, verbal or written, not set forth herein. 
 9.6 Assignment;
Change of Control. 
 This Agreement may not be assigned by Patheon without the prior written consent of Flexion. Notwithstanding the
foregoing, either Party may assign this Agreement to an Affiliate or to an acquirer or successor in interest in connection with a Change of Control of such Party without the prior written consent of the other Party, provided that such Party provides
the other Party with written notice of any such assignment. This Agreement shall be binding upon and inure to the benefit of Flexion and Patheon and their respective successors, heirs, executors, administrators, and permitted assigns.
“Change of Control” means the closing of (a) a merger, consolidation or similar transaction providing for the acquisition of the direct or indirect ownership of more than fifty percent (50%) of a Party’s shares or
similar equity interests or voting power of the outstanding voting securities or that represents the power to direct the management and policies of such Party (including any acquisition arising through the offering of any shares of Patheon or any of
its Affiliates on any securities or stock exchange), or (b) the sale of all or substantially all of a Party’s assets related to the subject matter of the Agreement. 

9.7 Amendment; Modification. This Agreement may not be amended, modified, altered, or supplemented except by a writing signed by both
Parties. No modification of any nature to this Agreement and no representation, agreement, arrangement, or other communication will be binding on the Parties unless such is expressly contained in writing and executed by the Parties as an amendment
to this Agreement. This Agreement may not be amended in any respect by any purchase order, invoice, acknowledgment, or other similar printed document issued by either Party. 

9.8 Subcontractors. Prior to subcontracting any of Patheon’s obligations hereunder, Patheon will notify Flexion (1) in
advance of engaging a proposed subcontractor that directly relates to the Manufacture of the Product and will obtain Flexion’s prior written approval of each such subcontractor, and (2) within six (6) months of all other
subcontractors so engaged. The terms of any subcontract will be in writing and will not be materially inconsistent with this 

  
 25 

 
Agreement or the Manufacturing and Supply Agreement, including Section 3.14 of the Manufacturing and Supply Agreement. No subcontracting will release Patheon from its responsibility for its
obligations under this Agreement. Patheon will be responsible for the work and activities of each subcontractor as they relate to performance of Patheon’s obligations under this Agreement, including compliance with the terms of this Agreement.

 9.9 Governing Law. 

(a) The laws of [...***...], whether procedural or substantive (but excluding application of any choice of law provisions contained
therein) shall apply to all matters pertaining only to (a) title to and ownership of Materials, Equipment or the Facility, and its appurtenances including, without limitation, all rights therein and the creation, exercise and extinction of such
rights, obligations and liabilities or (b) employment law matters. In relation to such matters, both Parties shall submit to the exclusive jurisdiction of the [...***...] Courts. For the avoidance of doubt, the Parties agree that nothing
in this Agreement shall (i) grant Flexion any property ownership rights in the Facility or (ii) shall constitute a lease to the Facility. 

(b) In all other respects, this Agreement shall be construed under and governed by the laws of [...***...] without regard to the
application of principles of conflicts of law. In relation to such matters, both Parties shall submit to the exclusive jurisdiction of the [...***...]. 

(c) Any preliminary issue over which of sub-section 9.9(a) or (b) applies to a particular claim or dispute shall be determined in
accordance with provisions of 9.9(a). 
 (d) The Parties expressly exclude the application of the United Nations Convention on Contracts for
the International Sale of Goods, if applicable. 
 9.10 Severability. If any provision of this Agreement is found by a proper
authority to be unenforceable, that provision to the extent it is found to be unenforceable or invalid will be severed and the remainder of the provision and this Agreement will continue in full force and effect. The Parties shall use their best
efforts to agree upon a valid and enforceable provision as a substitute for any invalid or unenforceable provision, taking in to account the Parties’ original intent of this Agreement. 

9.11 Construction. Unless the context of this Agreement otherwise requires: (a) words of any gender include each other gender;
(b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and derivative or similar words refer to this entire
Agreement; (d) the terms “Article,” “Section,” 

  
  

***Confidential Treatment Requested 
  

26 

 
“Exhibit,” or “clause” refer to the specified Article, Section, Exhibit, or clause of this Agreement; (e) “or” is disjunctive but not necessarily exclusive; and
(f) the term “including” or “includes” means “including without limitation” or “includes without limitation.” Whenever this Agreement refers to a number of days, such number will refer to calendar days
unless business days are specified. The captions and headings of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in
this Agreement. The language of this Agreement will be deemed to be the language mutually chosen by the Parties, and no rule of strict construction will be applied against either Party hereto. 

9.12 Third Party Beneficiaries. This Agreement is not intended to confer upon any non-party any right or remedy hereunder, except as
may be received or created as part of a valid assignment. 
 9.13 Further Assurances. Each of the Parties agrees to duly execute and
deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such additional assignments, agreements, documents, and instruments, that may be
necessary or as the other Party hereto may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party
its rights and remedies under, this Agreement. 
 9.14 Counterparts. This Agreement may be signed in counterparts, each and every one
of which will be deemed an original. Facsimile or PDF signatures will be treated as original signatures. 
 9.15 Taxes. 

(a) Subject to (b) and (c) below, Patheon will bear all Taxes however designated as a result of the provision of the Transfer
Services under this Agreement. 
 (b) Flexion acknowledges that it will be responsible for all Taxes that arise in respect of the following:

 (i) The acquisition of the Flexion-Supplied Materials. 

(ii) The acquisition of the Flexion Manufacturing Equipment. 

(c) Any payment due under this Agreement for the provision of Transfer Services to Flexion by Patheon is exclusive of value added or
equivalent tax in any other jurisdiction, including any related interest and penalties (hereinafter all referred to as “VAT”). If any VAT is payable on a Transfer Service supplied by Patheon to Flexion under this Agreement, this VAT
will be added to the invoice amount and will be for the account of (and reimbursable to Patheon by) Flexion. Where applicable, Patheon will use its reasonable commercial efforts to ensure that its invoices to Flexion are issued in such a way that
these invoices meet the requirements for deduction of input VAT by Flexion, to the extent permitted by law to do so. 

  
 27 

 (d) Flexion acknowledges that all amounts due in respect of any fees payable by Flexion under
this Agreement shall be paid in full without any set-off, counterclaim, deduction or withholding in respect of any Tax liabilities. 
 The
remainder of this page is left blank intentionally. 

  
 28 

 IN WITNESS WHEREOF, this Technical Transfer and Service Agreement has been executed by the
Parties hereto as of the day and year first written above. 
  

									
	PATHEON UK LIMITED:	 		 	FLEXION THERAPEUTICS, INC.:
					
	By:	 	 /s/ A.M. Botterill
	 		 	By:	 	 /s/ Michael D. Clayman, M.D.

					
	Name:	 	 A.M. Botterill
	 		 	Name:	 	 Michael D. Clayman, M.D.

					
	Title:	 	 Exec. Dir. & Gen. Manager
	 		 	Title:	 	 CEO

 Signature Page of Technical Transfer and Service Agreement 

  
 29 

 Exhibit 2.1-A 

[...***...] 

  
  

***Confidential Treatment Requested for pages 30-36. 

Omitted pages have been filed separately with the Commission. 

30-36 

 Exhibit 2.1-B 

[...***...] 

  
  

***Confidential Treatment Requested for pages 37-43. 

Omitted pages have been filed separately with the Commission. 

37-43 

 Exhibit 2.1-C 

[...***...] 

  
  

***Confidential Treatment Requested 

44 

 Exhibit 2.1-D 

[...***...] 

  
  

***Confidential Treatment Requested for pages 45-50. 

Omitted pages have been filed separately with the Commission. 

45-50 

 Exhibit 2.1-E 

[...***...] 

  
  

***Confidential Treatment Requested for pages 51-52. 

Omitted pages have been filed separately with the Commission. 

51-52 

 Exhibit 2.1-F 

[...***...] 

  
  

***Confidential Treatment Requested for pages 53-55. 

Omitted pages have been filed separately with the Commission. 

53-55 

 Exhibit 2.7 

Steering Committee 
 1. Generally.
The purpose of the Steering Committee shall be to oversee the Technical Transfer and Service Agreement, the Manufacturing and Supply Agreement and the Quality Agreement (the “Agreements”) and to facilitate communications between the
Parties with respect thereto. The Steering Committee shall have the responsibilities and authority allocated to it in this Exhibit 2.7. The Steering Committee shall have the obligation to exercise its authority consistent with the respective purpose
for the Steering Committee as stated herein and any such decisions shall be made in good faith. 
 2 Formation and Purpose. Promptly following the
Effective Date, the Parties shall confer and then create a Steering Committee. The Steering Committee shall have authority, subject to Paragraph 5, to oversee the priorities and budgets (not less than on a quarterly basis), to oversee manufacturing
and controls for the Products, to review and approve all associated regulatory filings and correspondence under the Agreements (including reviewing and approving itemized budgets with respect to the foregoing), to approve the projects and plans of
any subcommittee it establishes consistent with this authority and to review any concerns either Party may have concerning key employees employed by the Parties to provide the Transfer Services under the Technical Transfer Agreement and the Services
under the Manufacturing and Supply Agreement. 
 3 General Steering Committee Membership and Procedure. 

 

	 	(a)	Membership. Each Party shall designate an equal number of representatives (not to exceed three (3) for each Party) to the Steering Committee with appropriate expertise to serve as members of the Steering
Committee. The Steering Committee representatives must all be employees of such Party or an Affiliate of such Party, with the caveat that each Party may designate for the Steering Committee up to one (1) representative who is not an employee
if: (i) such non-employee representative agrees in writing to be bound to the terms of this Agreement for the treatment and ownership of confidential information of the Parties, and (ii) the other Party consents to the designation of such
non-employee representative, which consent shall not be unreasonably withheld. Each Party may replace its Steering Committee representatives at any time upon written notice to the other Party. The Steering Committee shall have a chairperson which
shall be appointed by Flexion. The chairperson of the Steering Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of the Steering Committee, and preparing and issuing minutes of each
meeting within fifteen (15) days thereafter. 

  

	 	(b)	 Meetings. The Steering Committee shall be constituted and the first meeting of the Steering Committee shall be held within sixty (60) days
following the Effective Date, with the Steering Committee considering finalization and approval of workplans prepared by the Parties for inclusion and commencement under the Agreements. Otherwise, the Steering Committee shall hold meetings at such
times as it elects to do so, but in no event shall such meetings be held less 

  
 56 

	 	
frequently than once every six (6) months. Meetings of the Steering Committee may be held in person or by means of telecommunication (telephone, video, or web conferences). To the extent
that the Steering Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Flexion selecting the first meeting location for the Steering Committee. A reasonable number of
additional representatives of a Party may attend meetings of the Steering Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in the Steering Committee. 

 

	 	(c)	Meeting Agendas. Each Party will disclose to the other proposed agenda items along with appropriate information at least three (3) business days in advance of each meeting of the Steering Committee;
provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to
such later addition of such agenda items or the absence of a specific agenda for the Steering Committee meeting. 

  

	 	(d)	Limitations of Steering Committee Powers. The Steering Committee shall have only such powers as are specifically delegated to it hereunder or from time to time as agreed to in writing by the mutual consent of the
Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, the Steering Committee shall not have any power to amend the Agreements. Any amendment to the terms and conditions of this
Agreement shall be implemented pursuant to Section 9.7 above. Additionally, no member of the Steering Committee shall be able to vote in the Steering Committee and thereby bind its respective Party on any material matter except as otherwise
properly authorized, approved, or delegated by such Party in accord with Paragraph 5. 

 4 Restrictions. Neither Party shall exercise
its right to finally resolve a dispute at the Steering Committee in accordance with this Paragraph 4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) expands the
obligations of the other Party under this Agreement; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged
breach of this Agreement; (v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable
law. 
 5 Authorization of Steering Committee Representatives. Each representative serving on the Steering Committee shall be responsible for
ensuring that he or she acts only as duly authorized by its respective Party and obtains any advance approvals, delegations, or other authorizations from his or her respective Party in advance of making any Steering Committee votes. 

  
 57EX-10.3

 Exhibit 10.3 

FIRST AMENDMENT OF LEASE 

AGREEMENT (“First Amendment”) made this 13 day of July, 2015 by and between CIP II/RJK 10-20 BMR Owner, LLC, 55 Cambridge Street,
Burlington, Massachusetts 01803 (hereinafter referred to as “Landlord”) and Flexion Therapeutics, Inc. (hereinafter referred to as “Tenant”). 

RECITALS 
 1.
Pursuant to that certain Lease dated February 22, 2013 by and between Landlord’s predecessor in interest, Mall Road Trust (“Original Landlord”) and Tenant (the “Existing Lease”), Landlord is leasing to Tenant those
certain premises known as 10 Burlington Mall Road, situated in Burlington, Massachusetts 01803, together with all improvements located thereon, consisting of 11,754 rentable square feet of area, all as more particularly described in said Existing
Lease (hereinafter referred to as the “Original Premises”). In addition, Landlord and Tenant entered into a letter agreement, dated June 28, 2015, regarding reimbursement responsibilities of Tenant for certain tenant improvement work
to the Suite 210 Space in the event that this First Amendment was not executed and delivered by the parties (the “June 28 Side Letter”). 

2. Landlord has succeeded to the Original Landlord’s interest as Landlord under the Lease, and all references to “Landlord” in
the Lease shall mean the Landlord as defined in this First Amendment at Landlord’s address above. 
 3. The parties desire to enter into
this First Amendment modifying and/or supplementing the provisions of the Existing Lease (and terminating the June 28 Side Letter), the effect of which will be (i) for Tenant to lease additional space consisting of approximately 4,715
square feet on the third floor of the Building contiguous to the Original Premises as shown on Exhibit A attached hereto (the “Phase I Expansion Space”), on the same terms and conditions as set forth in the Existing Lease, except as may be
modified herein; (ii) for Tenant to have the option to lease additional space consisting of approximately 5,405 square feet on the third floor of the Building contiguous to the Phase I Expansion Space as shown on Exhibit A attached hereto (the
“Phase II Expansion Space”), on the same terms and conditions as set forth in the Existing Lease, except as may be modified herein; (iii) for Tenant to lease on a temporary basis approximately 6,748 square feet on the second floor of
the Building known as Suite 210 (the “Suite 210 Temporary Space”), on the same terms and conditions as set forth in the Existing Lease, except as may be modified herein; (iv) to extend the term of the Existing Lease for the Original
Premises through October 31, 2019; and (v) to further amend the Existing Lease in certain respects, all upon the terms and conditions set forth below. The Original Premises, the Phase I Expansion Space and the Phase II Expansion Space (if
applicable) collectively are hereinafter referred to as the “2016 Combined Space.” 
 4. All of the terms, covenants and conditions
of the Existing Lease which are not inconsistent with the terms hereinafter set forth shall apply, as applicable, to the 2016 Combined Space and the Suite 210 Temporary Space. 

5. Capitalized terms used herein and not defined shall have the meanings ascribed to such terms in the Existing Lease and the Existing Lease as
amended by this First Amendment is hereby known as the “Lease”. 
 6. The term “Premises” used in the Existing Lease
shall include where appropriate the Original Premises, and, as and when leased pursuant to this Amendment, the Phase I Expansion Space, the Phase II Expansion Space, and the Suite 210 Temporary Space. 

IN CONSIDERATION of the mutual covenants contained herein, the parties agree as follows: 

A. Term of Lease. 
 The
term for the Phase I Expansion Space shall commence upon substantial completion of Landlord’s Work, as hereinafter defined (the “Phase I Expansion Space Commencement Date”), which is anticipated to occur on May 1, 2016 (the
“Target Delivery Date”), and expire on October 31, 2019. In addition, upon execution of this First Amendment, notwithstanding any provision of the Existing Lease to the contrary, the term of the Existing Lease shall not expire on
October 31, 2016, but shall instead be extended for three (3) years and shall expire on October 31, 2019 (the “Termination Date”), unless sooner terminated or otherwise extended in accordance with the terms and provisions of
the Lease. 

 B. Suite 210 Temporary Space. 

(i) Landlord hereby leases to Tenant, and Tenant hereby agrees to lease, the Suite 210 Temporary Space, commencing upon
substantial completion by Landlord of the tenant improvements shown on the space plan and specifications attached hereto as Exhibit B, on a turnkey basis, using finishes similar to the finishes in the Original Premises, except that Tenant shall be
responsible at Tenant’s sole cost and expense for furnishing and installing all wiring whips, wiring within furniture and all telephone and data wiring required by Tenant. If Landlord does not deliver the Suite 210 Temporary Space to Tenant,
with such turnkey improvements substantially complete, by September 1, 2015, then, in addition to any other abatements of rent applicable hereunder, for each day of such delay in delivery after September 1, 2015, Tenant shall receive a
credit of one day of Fixed Rent for the Suite 210 Temporary Space to be applied against the next rent due under the Lease. In the event that the Suite 210 Temporary Space is not tendered to Tenant by October 15, 2015, then Tenant shall also
have the right, in lieu of such abatement, to terminate the Lease with respect to the Phase I Expansion Space, the Phase II Expansion Space (if applicable) and/or the Suite 210 Temporary Space, without the payment of any termination fee or other
such payment. 
 (ii) Landlord shall contribute Twenty Dollars ($20.00) per square foot, equal to One Hundred Thirty-Four
Thousand Nine Hundred Sixty Dollars ($134,960.00), and Tenant shall contribute up to Ten Dollars ($10.00) per square foot, equal to Sixty-Seven Thousand Four Hundred Eighty Dollars ($67,480.00), toward the costs of the tenant improvements for the
Suite 210 Temporary Space, with Tenant’s payment to Landlord for such costs due and payable within ten (10) days after delivery of the Suite 210 Temporary Space to Tenant. Any costs in excess of Thirty Dollars ($30.00) per square foot,
equal to Two Hundred Two Thousand Four Hundred Forty Dollars ($202,440.00), for the tenant improvements for the Suite 210 Temporary Space shall be borne by Landlord unless such costs are incurred as a direct result of change orders or deviations
requested by Tenant from the plan and specifications set forth on Exhibit B attached hereto or as a direct result of Tenant Delays. 

(iii) Commencing upon delivery of the Suite 210 Temporary Space by Landlord to Tenant, Tenant shall pay Fixed Annual Rent for
the Suite 210 Temporary Space in the amount of Two Hundred Nineteen Thousand Three Hundred Ten Dollars ($219,310.00) per annum, payable in equal monthly installments of Eighteen Thousand Two Hundred Seventy-Five and 83/100 Dollars ($18,275.83),
prorated for any partial month. 
 (iv) Tenant shall pay to Landlord, together with the monthly installment of Annual Fixed
Rent, (x) Nine Hundred Eighty Four and 08/100 Dollars ($984.08) per month, prorated for any partial month, for electricity for the Suite 210 Temporary Space, based on a rate of $1.75 per square foot per year (y) if Tenant exercises its
right under Section, B(vi)(x) below, the amount by which Landlord’s Tax Expenses allocable to the Suite 210 Temporary Space exceed Base Taxes allocable to the Suite 210 Temporary Space (Base Taxes for purposes of this clause (y) meaning
Landlord’s Tax Expense budget for fiscal year 2016), and (z) if Tenant exercises its right under Section, B(vi)(x) below, the amount by which Operating Expenses allocable to the Suite 210 Temporary Space exceed Base Operating Expenses
allocable to the Suite 210 Temporary Space (Base Operating Expenses for purposes of this clause (z) meaning Landlord’s Operating Expense budget for calendar year 2016). 

(v) Tenant shall vacate and surrender the Suite 210 Temporary Space within thirty (30) days after delivery of the Phase I
Expansion Space by Landlord to Tenant, unless Tenant has the right to exercise and does exercise the Suite 210 Right of First Refusal, as hereinafter defined. If Tenant does not exercise such right, Tenant shall remove all of Tenant’s fixtures,
furniture and equipment from the Suite 210 Temporary Space and otherwise yield up the Suite 210 Temporary Space to Landlord in accordance with the provisions of the Lease (it being understood, however, that Tenant shall have no obligation to remove
any wiring or improvements made to the Suite 210 Temporary Space). In the event that Tenant fails to vacate and surrender the Suite 210 Temporary Space as set forth above on or before thirty (30) days after delivery of the Phase I Expansion
Space by Landlord to Tenant, Landlord hereby reserves all of its rights and remedies under the Lease for such holdover. 

 (vi) Notwithstanding the foregoing provisions of subsection (v), if Tenant
exercises its Termination Option with respect to the Phase I Expansion Space in accordance with the provisions of Section K of this First Amendment, at the time of giving notice to Landlord of such termination Tenant shall also deliver written
notice to Landlord either (x) extending the term of the Suite 210 Temporary Space to October 31, 2019, coterminous with the term for the Original Premises, upon all of the terms and conditions contained in this First Amendment, including
payment of Annual Fixed Rent in accordance with the schedule set forth in Section C below (prorated, however, based upon the size of the Suite 210 Temporary Space), or (y) terminating its lease of the Suite 210 Temporary Space, which
termination shall be effective nine (9) months after the date of such notice, and Tenant shall vacate and surrender the Suite 210 Temporary Space within such nine (9) month period. In the event that Tenant fails to vacate and surrender the
Suite 210 Temporary Space within such period, Landlord hereby reserves all of its rights and remedies under the Lease for such holdover. 

(vii) The June 28 Side Letter is hereby terminated by Landlord and Tenant and is, accordingly, void and of no force or
effect. 
 C. Annual Fixed Rent. 

Tenant and Landlord acknowledge and agree that Annual Fixed Rent for the Original Premises shall be payable in the amount set forth in
Section 1.1 of the Existing Lease until October 31, 2016. Thereafter, Annual Fixed Rent for the Original Premises shall be included in the following Annual Fixed Rent schedule for the Phase I Expansion Space, which shall be effective as of
the Phase I Expansion Space Commencement Date: 
 (i) For the period from May 1, 2016 through July 31, 2016 the sum
of $0, payable in monthly installments of $0; * 
 (ii) For the period from August 1, 2016 through October 31,
2016, the sum of $38,309.37 based on $32.50 per square foot, payable in monthly installments of $12,769.79; 
 (iii) For the
period from November 1, 2016 through October 31, 2017, the sum of $551,711.50 based on $33.50 per square foot, payable in monthly installments of $45,975.96; ** 

(iv) For the period from November 1, 2017 through October 31, 2018, the sum of $568,180.50 based on $34.50 per square
foot, payable in monthly installments of $47,348.38; and ** 
 (v) For the period from November 1, 2018 through
October 31, 2019, the sum of $584,649.50 based on $35.50 per square foot, payable in monthly installments of $48,720.79. ** 
  

	*	This schedule assumes the Phase I Expansion Space Commencement Date will occur on the Target Delivery Date. If for any reason the Phase I Expansion Space Commencement Date does not occur on the Target Delivery Date,
this schedule will be adjusted so that Annual Fixed Rent for the first three months after the Phase I Expansion Space Commencement Date occurs is abated, provided, however, that the dates of the Annual Fixed Rent increases set forth in the schedule
above will remain unchanged. 

	**	Includes the Original Premises 

 Monthly installments of Base Rent shall be payable in advance
on the first day of each month during the term of this Lease without deduction, set-off, prior notice or demand in lawful money of the United States of America. The rent payment for any fractional month at the commencement, termination or expiration
of the Lease term will be prorated. 
 D. Tenant Electricity. 

Landlord and Tenant acknowledge and agree that the Phase I Expansion Space and the Phase II Expansion Space, if applicable, will be check
metered for electric usage. Tenant shall be separately billed by Landlord, as Additional Rent, for all electricity usage related to and/or used respecting the Phase I Expansion Space and the Phase II Expansion Space, if applicable, and all related
facilities and equipment (the “Premises Electric”) based on readings of such check meter (at Landlord’s actual cost of electricity for such amount of electricity shown to be consumed at the Phase I Expansion Space and the Phase II
Expansion Space, if applicable, on such check meter). Landlord shall have the right to bill Tenant for the Premises Electric on a monthly basis based on such check meter and Tenant shall pay such Premises Electric charges to Landlord within thirty
(30) days after receipt of Landlord’s billing therefor. Landlord’s failure to bill Tenant on a monthly 

 
basis shall in no way waive Tenant’s payment obligations with respect to the Premises Electric charges. If the Phase I Expansion Space and the Phase II Expansion Space, if applicable, cannot
be check metered (in Landlord’s sole reasonable judgment based upon the costs of such check metering), Tenant shall be billed its proportionate share for Tenant’s electricity. 

E. Real Estate Taxes. 
 For
the Original Premises, until October 31, 2016 Tenant shall continue to pay the amount by which Landlord’s Tax Expenses allocable to the Premises exceed Base Taxes allocable to the Premises in accordance with the Existing Lease. For the
Phase I Expansion Space and the Phase II Expansion Space, if applicable, until October 31, 2016 Tenant shall pay the amount by which Landlord’s Tax Expenses allocable to the Phase I Expansion Space and the Phase II Expansion Space, if
applicable, exceed Base Taxes allocable to the Phase I Expansion Space and the Phase II Expansion Space, if applicable (Base Taxes for purpose of this sentence meaning Landlord’s Tax Expense budget for fiscal year 2016). Commencing on
November 1, 2016, Tenant shall pay the amount by which Landlord’s Tax Expenses allocable to the 2016 Combined Space exceed Base Taxes allocable to the 2016 Combined Space (Base Taxes for purpose of this sentence meaning Landlord’s Tax
Expense budget for fiscal year 2017). 
 F. Operating Expenses. 

For the Original Premises, until October 31, 2016 Tenant shall continue to pay as Additional Rent the amount by which Operating Expenses
Allocable to the Premises exceed Base Operating Expenses Allocable to the Premises in accordance with the Existing Lease. For the Phase I Expansion Space and the Phase II Expansion Space, if applicable, until October 31, 2016 Tenant shall pay
the amount by which Landlord’s Operating Expenses allocable to the Phase I Expansion Space and the Phase II Expansion Space, if applicable, exceed Base Operating Expenses allocable to the Phase I Expansion Space and the Phase II Expansion
Space, if applicable (Base Operating Expenses for purpose of this sentence meaning Landlord’s Operating Expense budget for calendar year 2016). Commencing on November 1, 2016, Tenant shall pay the amount by which Landlord’s Operating
Expenses allocable to the 2016 Combined Space exceed Base Operating Expenses allocable to the 2016 Combined Space (Base Operating Expenses for purpose of this sentence meaning Landlord’s Operating Expense budget for calendar year 2016). 

G. Landlord’s Work. 

Landlord shall provide a turnkey build-out of the Phase I Expansion Space, and the Phase II Expansion Space, if applicable, using the same
finishes and materials (if available) as used in the Original Premises (including, but not limited to, lighting, carpet, paint, doors and sidelights), in accordance with the plan and specifications attached hereto as Exhibit A. 

H. Target Delivery Date; Delay in Commencement 
  

	 	(i)	Tenant acknowledges and agrees that the Target Delivery Date is based on the existing tenant (as of the date of this First Amendment) in the Phase I Expansion Space (the “Existing Tenant”), vacating its
premises on February 1, 2016. If the Existing Tenant does not vacate the Phase I Expansion Space by February 1, 2016, the Target Delivery Date shall be extended on a day for day basis until the Existing Tenant vacates the Phase I Expansion
Space. Notwithstanding the Target Delivery Date, if for any reason Landlord cannot deliver possession of the Phase I Expansion Space to Tenant on or before the Target Delivery Date, Landlord shall not be subject to any liability therefor, nor shall
such failure affect the validity of this Lease or Tenant’s obligations hereunder, except as set forth herein, and, in any event, Landlord shall use commercially reasonable efforts to cause the Existing Tenant to vacate as quickly as possible,
and Landlord shall not grant the Existing Tenant any right to stay in such space beyond February 1, 2016. In such event, however, Tenant shall not be obligated to pay Annual Fixed Rent or additional rent for the Phase I Expansion Space, and
(except to the extent that such delay in delivery of the Phase I Expansion Space was caused by Tenant Delay or events outside of Landlord’s control, but subject to Section H(iii) below) Annual Fixed Rent for the Suite 210 Temporary Space shall
also be abated, until possession of the Phase I Expansion Space is tendered to Tenant and without requirement of further act of the parties the Termination Date of the Lease shall be extended by a period equal to the period between the Target
Delivery Date and the occurrence of the Phase I Expansion Space Commencement Date. 

  

	 	(ii)	In the case of an event of Tenant Delay, Landlord’s Work shall be deemed substantially completed as of the date when Landlord’s Work would have been completed but for any Tenant Delays, as determined by
Landlord in the exercise of its good faith business judgement. 

	 	(iii)	In the case of events outside of Landlord’s Control (other than events of Tenant Delay) Tenant shall not be obligated to pay Annual Fixed Rent or additional rent for the Phase I Expansion Space, and Annual Fixed
Rent for the Suite 210 Temporary Space shall also be abated from the date that is thirty (30) days after the Target Delivery Date, until possession of the Phase I Expansion Space is tendered to Tenant and, without requirement of further act of
the parties the Termination Date of the Lease shall be extended by a period equal to the period between the Target Delivery Date and the occurrence of the Phase I Expansion Space Commencement Date; provided that the Termination Date shall not be
extended to a date that is later than January 31, 2020. 

  

	 	(iv)	In the event that the Phase I Expansion Space is not tendered to Tenant by August 1, 2016, then Tenant shall also have the right, in lieu of such abatement, to terminate the Lease with respect to the Phase I Expansion
Space, Phase II Expansion Space (if applicable) and/or the Suite 210 Temporary Space, without the payment of any termination fee or other such payment. Landlord may, but shall not be required to, confirm the Phase I Expansion Space Commencement Date
by written notice to Tenant; any such notice by Landlord shall be conclusive with respect to the Phase I Expansion Space Commencement Date. 

I. Renewal Option. 
 Tenant
shall have the right to extend the term of the Lease for a portion of, or the entire, 2016 Combined Space for one (1) period of three (3) years upon and subject to all of the terms and conditions set forth in Section 9.18 of the
Original Lease. 
 J. Phase II Expansion Space Option. 

Tenant shall have the option to expand into the Phase II Expansion Space by delivering written notice to Landlord exercising such option prior
to October 1, 2015, in which case Tenant will lease the Phase II Expansion Space upon all of the applicable terms set forth in this First Amendment (including, without limitation, the per square foot Fixed Rent amounts (including the provision
of three (3) months of free rent) and the applicable abatement and termination rights hereof) and Section I of Exhibit C. Notwithstanding the foregoing. Tenant acknowledges that Landlord is currently marketing the Phase II Expansion Space to
third parties, however Landlord agrees that Landlord will not enter into a lease with a third party for the Phase II Expansion Space prior to October 1, 2015 unless Tenant waives its right to expand into the Phase II Expansion Space. On and
after October 1, 2015, Tenant have a right of first refusal to lease the Phase II Expansion Space in accordance with the terms and conditions set forth on Exhibit C attached hereto. If Tenant exercises its option to expand into the Phase II
Expansion Space prior to October 1, 2015, Tenant shall also have a right of first refusal to lease the Suite 210 Temporary Space in accordance with the terms and conditions set forth on Exhibit E attached hereto. 

K. Termination Option. 
  

	 	(a)	Tenant shall have the right to terminate the Lease with respect to all or a portion of the Temporary Space, the Phase I Expansion Space and/or the Phase II Expansion Space, but not with respect to the Original Premises,
prior to the expiration of the term, upon nine (9) months advance written notice (or such lesser period as may be remaining in the term) (the “Termination Notice”) delivered within sixty (60) days of the occurrence of a
Triggering Event (the “Termination Option”); provided however, that the Parties agree that if such Termination Notice is delivered prior to the Phase I Expansion Space Commencement Date, Tenant shall not occupy the Phase I Expansion Space
or the Phase II Expansion Space (if applicable) but shall continue to occupy the Suite 210 Temporary Space through the date that is nine (9) months from the Termination Notice. “Triggering Event” means the date upon which
(i) Tenant determines, in good faith, that its lead product candidate, FX006 (the Tenant’s sustained-release intra-articular steroid for the treatment of osteoarthritis), fails to meet the pre-defined endpoints (as defined in the
applicable protocol and further defined in Exhibit D of this First Amendment) with respect to the ongoing phase 2(b) clinical trial comparing FX006 against placebo, which Tenant reasonably determines, in good faith, will result in an adverse effect
on Tenant’s business, or (ii) Tenant’s receipt of a complete response letter or non-approvable letter from the FDA (as defined in Exhibit D of this First Amendment) with respect to the filing of a New Drug Application relating to
FX006, which reasonably will result in an adverse effect on Tenant’s business (which may include, by way of example, but without limitation, restructuring of the business or a reduction in force). 

	 	(b)	In the event Tenant exercises its Termination Option prior to May 1, 2016, Tenant shall pay the following, in addition to the monthly rent for the 210 Temporary Space (as set forth in B(iii) above) for the nine
month notice period set forth in Section K(a) above: 

  

	 	(i)	All unamortized brokerage fees (to extent actually paid by Landlord) as of the date which is nine (9) months after the date of the Termination Notice; 

 

	 	(ii)	An amount equal to $73,103.32 (representing four months of rent due on the 210 Temporary Space); 

  

	 	(iii)	An amount equal to $33,740 (representing payment for an additional $5.00 per square foot on the Suite 210 Temporary Space above the $10.00 per square foot which may have been paid pursuant to Section B above);

  

	 	(iv)	The unamortized amount of Landlord’s documented costs through the date of the Termination Notice, including all non-canceable costs and materials purchased, incurred prior ot the date of the Termination Notice, for
tenant improvements for the Phase I Expansion Space and the Phase II Expansion Space (if applicable); provided that, Landlord agrees (1) that such costs (or commitment for such costs) for tenant improvements will not commence prior to
February 1, 2016 (other than expenditures related to architectural and engineering fees), and (2) to use commercially reasonable efforts to mitigate the amount of such costs. 

 

	 	(c)	In the event Tenant exercises its Termination Option after May 1, 2016 and prior to December 31, 2017, Tenant shall pay the following, in addition to the monthly rent for the Phase I Expansion Space and Phase
II Expansion Space (if occupied by Tenant) (as set forth in (C) above) for the nine month notice period set forth in Section K(a) above: 

  

	 	(i)	All unamortized brokerage fees and legal fees as of the date which is nine (9) months after the date of the Termination Notice taking into account, for purposes of amortization, the four (4) monthly
installments paid pursuant to K(c)(ii) below; 

  

	 	(ii)	An amount equal to four (4) monthly installments of Annual Fixed Rent being paid by Tenant at such time for the applicable space being terminated; and 

 

	 	(iii)	The unamortized amount of Landlord’s documented costs through the date of the Termination Notice, including all non-canceable costs and materials purchased, incurred prior ot the date of the Termination Notice, for
tenant improvements for the Phase I Expansion Space and the Phase II Expansion Space (if applicable). 

  

	 	(d)	In the event Tenant exercises its Termination Option after December 31, 2017, Tenant shall pay the following, in addition to the monthly rent for the Phase I Expansion Space and Phase II Expansion Space (if
occupied by Tenant) (as set forth in (C) above) for the nine month notice period set forth in Section K(a) above: 

  

	 	(i)	All unamortized brokerage fees and legal fees as of the date which is nine (9) months after the date of the Termination Notice taking into account, for purposes of amortization, the three (3) monthly
installments paid pursuant to K(d)(ii) below; 

  

	 	(ii)	An amount equal three (3) monthly installments of Annual Fixed Rent being paid by Tenant at such time for the applicable space being terminated; and 

 

	 	(iii)	The unamortized amount of Landlord’s documented costs through the date of the Termination Notice, including all non-canceable costs and materials purchased, incurred prior ot the date of the Termination Notice, for
tenant improvements for the Phase I Expansion Space and the Phase II Expansion Space (if applicable). 

 L. Brokerage.
The Tenant has not dealt with any broker or agent other than The Shaffer Company in connection with the negotiation or execution of this First Amendment. Tenant agrees to indemnify Landlord against any costs incurred by Landlord (including
reasonable attorneys’ fees) if the foregoing representation is untrue. The foregoing indemnification obligation shall survive the expiration or any termination of the Lease, as amended by this First Amendment. 

M. Ratification of Lease. Except as amended and modified by this First Amendment, all the terms, provisions, agreements, covenants and
conditions of the Lease are hereby affirmed and ratified. From and after the date hereof, all references to the Lease or Lease shall mean the Lease or Lease as amended hereby and to the extent that there any inconsistencies between this

 
First Amendment and the Lease, this First Amendment shall control. Landlord and Tenant each hereby ratifies and confirms its obligations under the Lease, and represents and warrants to the other
that, to its knowledge, it has no defenses thereto. Additionally, Landlord and Tenant further confirm and ratify that, as of the date hereof, (a) the Landlord and Tenant are and remain in good standing and the Lease is in full force and effect,
and (b) neither Landlord nor Tenant has any claims, counterclaims, set-offs or defenses against the other arising out of the Lease or in any way relating thereto or arising out of any other transaction between Landlord and Tenant. 

N. Execution/Entire Agreement. This First Amendment, together with the Lease as affected hereby, constitutes the entire agreement of the
parties, and may not be amended except by written instrument signed by all parties. This First Amendment shall have the effect of an agreement under seal and shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and assigns. This First Amendment may be executed in counterparts all of which taken together shall constitute an original executed document. 

[Signatures on following page] 

 The parties hereto have hereunto set their hands and seals the day and year first above written.

  

			
	LANDLORD: CIP II/RJK 10-20 BMR Owner, LLC
	
	 /s/ Brandon Kelly

	BY:	 	Brandon Kelly
	ITS:	 	
	
	TENANT: FLEXION THERAPEUTICS, INC.
	
	 /s/ Michael Clayman

	BY:	 	Michael Clayman
	ITS:	 	CEO

 EXHIBIT A 

Plan of Phase I Expansion Space and Phase II Expansion Space 
  

 
 

 
  

	*	Please note Landlord shall provide a new egress door through the coset area pointed out by the red arrow. 

 Exhibit A-1 

Scope of work for Phase I Expansion Space 
  

	 	1.	Carpentry 

  

	 	a.	All new walls built to drop ceiling as shown on mutually agreed upon plan. 

  

	 	b.	Installation of kitchen cabinets (uppers and lowers) in kitchen area. 

  

	 	2.	Millwork 

  

	 	a.	Kitchen—cabinets (uppers and lowers) as shown on Exhibit A. Cabinets to have plastic laminate finish, specific layout to be mutually agreed upon by Landlord and Tenant. Cabinet and countertop laminate to be
mutually agreed upon by Landlord and Tenant based on Landlord’s building standards. 

  

	 	3.	Doors and hardware 

  

	 	a.	Provide 3’0” x 8’4” solid wood doors paint grade and building standard bright chrome latch sets. 

  

	 	b.	Provide painted hollow metal door frames to match door size, as shown in Exhibit A. 

  

	 	c.	All doors and frames shall be painted to match existing space. 

  

	 	d.	All electronic access control components and labor to be provided and installed by the Tenant. 

  

	 	4.	Glazing 

  

	 	a.	Provide Landlords upgraded sidelights to have 1/4” tempered glass, framed to match door frame from floor to door height, 48” wide in all new offices and the conference room. 

 

	 	b.	Tenant shall, at Tenant’s expense, provide any necessary connections to Premises main glass entry doors required to incorporate Tenant’s security access system into the Building fire protection systems.

  

	 	c.	All glazing film shall be purchased and installed by Landlord’s contractor at Landlord’s expense. Landlord to provide glazing film to match existing space. 

 

	 	5.	Ceilings 

  

	 	a.	Provide 2x2 Armstrong Dune Tegular ceiling tiles, style number 1774 (or similar Landlord standard), on Armstrong 15/16” grid for all areas of drop ceiling. 

 

	 	6.	Flooring 

  

	 	a.	Provide Armstrong Commercial VCT in Kitchen with 4” Vinyl cove base, colors and pattern to be mutually agreed upon by Landlord and Tenant based on Landlord’s building standards. 

 

	 	b.	Provide Carpet tile to be mutually agreed upon by Landlord and Tenant based on Landlord’s building standards in all offices and open areas as shown in Exhibit A. Landlord will provide a matching/coordinating carpet
to Tenant’s existing carpet. 

  

	 	c.	Transitions to be black vinyl as appropriate for materials. 

  

	 	7.	Paint shall be Benjamin Moore or mutually agreed upon equivalent to match Tenant’s existing paint colors. 

  

	 	8.	Plumbing & Appliances 

  

	 	a.	Landlord shall provide a standard stainless steel sink and faucet for Kitchen. 

  

	 	9.	Fire Protection 

  

	 	a.	Landlord to provide complete sprinkler coverage as required by local codes. 

  

	 	b.	Landlord shall provide fire extinguishers as required by local regulations and codes. 

  

	 	c.	Tenant, at its sole cost and expense, shall be responsible for all equipment and installation of any dedicated supplemental fire protection systems (preaction systems) in Server Room, if applicable. 

 

	 	10.	HVAC 

  

	 	a.	Landlord shall rework existing HVAC as needed to provide adequate base heating and cooling within the space. 

  

	 	b.	Tenant shall be responsible for any additional HVAC in server room or IT rooms. 

	 	c.	Landlord shall provide operable thermostats spaced according to existing and reasonable zoning, and controls shall be tied into the existing building’s energy management system. 

 

	 	d.	Landlord shall provide air balancing at completion of project. 

  

	 	11.	Electrical 

  

	 	a.	Power 

  

	 	i.	Landlord shall equip each office with a minimum of 2 duplex outlets. 

  

	 	ii.	Tenant to provide furniture that is prewired for power and is coordinated with the electrician’s power plan. 

  

	 	b.	Lighting 

  

	 	i.	Landlord shall provide 2”x4” direct indirect LED light fixtures. 

  

	 	ii.	Landlord shall provide building standard emergency and night lighting as required by local regulations and code. 

  

	 	12.	All Furnishings are not included in the scope of work and shall be the responsibility of the Tenant. 

  

	 	13.	ALL WIRING WHIPS, WIRING WITHIN FURNITURE, AND ALL TELEPHONE AND DATA WIRING ARE NOT INCLUDED IN THIS SCOPE OF WORK AND SHALL BE THE RESPONSIBILITY OF THE TENANT. 

Notes: 
  

	 	•	 	All work to be completed in accordance with approved plans and construction schedule. 

  

	 	•	 	Legal removal and disposal of work related debris is included. 

  

	 	•	 	We have assumed all work to be done between the hours of 7:00am to 5:00pm unless otherwise specified. No Premium Time included. 

  

	 	•	 	Mutually agreed upon substitutions for any products mentioned herein may be used contingent upon product availability, supplier pricing increases and timing. 

 

	 	•	 	Any products and/or labor not stated to be performed in the above description is not included in this scope of work. Any deviations from this scope of work may result in a change order, the cost of which shall be paid
for by Tenant. 

 EXHIBIT B 

Plan of Suite 210 Temporary Space 
  

 

 Exhibit B-1 

Scope of work for Suite 210 (Temporary Space) 
  

	 	14.	Carpentry 

  

	 	a.	All new walls built to drop ceiling as shown on mutually agreed upon plan. 

  

	 	b.	Installation of kitchen cabinets (uppers and lowers) in kitchen area. 

  

	 	c.	Provide plywood backing for electrical and Tel/Data use in server room and electric room as needed. 

  

	 	15.	Millwork 

  

	 	a.	Kitchen–cabinets (uppers and lowers) as shown on Exhibit B. Cabinets to have plastic laminate finish, specific layout to be mutually agreed upon by Landlord and Tenant. Cabinet and countertop laminate to be
mutually agreed upon by Landlord and Tenant based on Landlord’s building standards. 

  

	 	16.	Doors and hardware 

  

	 	a.	Provide 3’0” x 8’4” solid wood doors paint grade and building standard bright chrome latch sets. 

  

	 	b.	Provide painted hollow metal door frames to match door size, as shown in Exhibit B. 

  

	 	c.	All doors and frames shall be painted to match existing space. 

  

	 	d.	All electronic access control components and labor to be provided and installed by the Tenant. 

  

	 	17.	Glazing 

  

	 	a.	Provide Landlords upgraded sidelights to have 1/4” tempered glass, framed to match door frame from floor to door height, 48” wide. 

 

	 	b.	Tenant shall, at Tenant’s expense, provide any necessary connections to Premises main glass entry doors required to incorporate Tenant’s security access system into the Building fire protection systems.

  

	 	c.	All glazing film shall be purchased and installed by Landlord’s contractor at Landlord’s expense. Landlord to provide glazing film to match existing space. 

 

	 	18.	Ceilings 

  

	 	a.	Provide 2x2 Armstrong Dune Tegular ceiling tiles, style number 1774 (or similar Landlord standard), on Armstrong 15/16” grid for all areas of drop ceiling. 

 

	 	19.	Flooring 

  

	 	a.	Provide Armstrong Commercial VCT in Kitchen with 4” Vinyl cove base, colors and pattern to be mutually agreed upon by Landlord and Tenant based on Landlord’s building standards. 

 

	 	b.	Provide Armstrong Commercial VCT in Server room and IT space as shown in Exhibit B. 

  

	 	c.	Provide Carpet tile to be mutually agreed upon by Landlord and Tenant based on Landlord’s building standards in all offices and open areas as shown in Exhibit B. Landlord will provide a matching/coordinating carpet
to Tenant’s existing carpet. 

  

	 	d.	Transitions to be black vinyl as appropriate for materials. 

  

	 	20.	Paint shall be Benjamin Moore or mutually agreed upon equivalent to match Tenant’s existing paint colors. 

  

	 	21.	Plumbing & Appliances 

  

	 	a.	Landlord shall provide a standard stainless steel sink and faucet for Kitchen. 

  

	 	22.	Fire Protection 

  

	 	a.	Landlord to provide complete sprinkler coverage as required by local codes. 

  

	 	b.	Landlord shall provide fire extinguishers as required by local regulations and codes. 

  

	 	c.	Tenant, at its sole cost and expense, shall be responsible for all equipment and installation of any dedicated supplemental fire protection systems (preaction systems) in Server Room, if applicable. 

	 	23.	HVAC 

  

	 	a.	Landlord shall rework existing HVAC as needed to provide adequate base heating and cooling within the space. 

  

	 	b.	Tenant shall be responsible for any additional HVAC in server room or IT rooms. 

  

	 	c.	Landlord shall provide operable thermostats spaced according to existing and reasonable zoning, and controls shall be tied into the existing building’s energy management system. 

 

	 	d.	Landlord shall provide air balancing at completion of project. 

  

	 	24.	Electrical 

  

	 	a.	Power 

  

	 	i.	Landlord shall equip each office with a minimum of 2 duplex outlets. 

  

	 	ii.	Tenant to provide furniture that is prewired for power and is coordinated with the electrician’s power plan. 

  

	 	b.	Lighting 

  

	 	i.	Landlord shall provide approximately 60, 2“x4” direct indirect LED light fixtures. 

  

	 	ii.	Landlord shall provide building standard emergency and night lighting as required by local regulations and code. 

  

	 	25.	All Furnishings are not included in the scope of work and shall be the responsibility of the Tenant. 

  

	 	26.	ALL WIRING WHIPS, WIRING WITHIN FURNITURE, AND ALL TELEPHONE AND DATA WIRING ARE NOT INCLUDED IN THIS SCOPE OF WORK AND SHALL BE THE RESPONSIBILITY OF THE TENANT. 

Notes: 
  

	 	•	 	All work to be completed in accordance with approved plans and construction schedule. 

  

	 	•	 	Legal removal and disposal of work related debris is included. 

  

	 	•	 	We have assumed all work to be done between the hours of 7:00am to 5:00pm unless otherwise specified. No Premium Time included. 

  

	 	•	 	Mutually agreed upon substitutions for any products mentioned herein may be used contingent upon product availability, supplier pricing increases and timing. 

 

	 	•	 	Any products and/or labor not stated to be performed in the above description is not included in this scope of work. Any deviations from this scope of work may result in a change order, the cost of which shall be paid
for by Tenant. 

 EXHIBIT C 

Right of First Refusal - Phase II Expansion Space 

1. Tenant shall have the exclusive right of first refusal to expand into the Phase II Expansion Space on the conditions hereinafter set forth
and to be exercised as hereinafter provided: 
 (a) No default by Tenant shall be existing or continuing in the performance
of any of the terms, covenants and conditions of this Lease in respect of a matter as to which notice of default has been given hereunder; provided, however, that in the event of any default that cannot with due diligence be cured prior to the last
date on which Tenant is entitled to exercise such right Tenant may nevertheless exercise such right of first refusal if Tenant shall have proceeded promptly after the service of any notice of default to commence to cure the default, and thereafter
completes the curing of the default with due diligence. 
 (b) Tenant shall accept the Phase II Expansion Space on the
following terms, and otherwise upon all of the applicable terms set forth in this First Amendment: 
 (i) The commencement
date of the term for the Phase II Expansion Space shall occur upon substantial completion of tenant improvements by Landlord (the “Phase II Expansion Space Commencement Date”), the cost of which tenant improvements shall be equivalent on a
per square foot basis to the cost for the Phase I Expansion Space tenant improvements (which shall be determined within sixty (60) days after the Phase I Expansion Space Commencement Date) but prorated based on the length of the Phase II
Expansion Space term; 
 (ii) Payment of Annual Fixed Rent by Tenant for the Phase II Expansion Space shall commence ninety
(90) days after the Phase II Expansion Space Commencement Date and shall be calculated by multiplying the square footage of the Phase II Expansion Space by the then applicable rent per square foot set forth in Section C of this First Amendment
at the time that Landlord delivers the Phase II Expansion Space to Tenant, with increases corresponding to the increases set forth in Section C; 

(iii) The Phase II Expansion Space term shall expire on the Termination Date for the Original Premises and the Phase I
Expansion Space. 
 2. Tenant shall exercise its right of first refusal in the following manner: Landlord shall notify Tenant at the
Premises that Landlord has entered into a letter of intent with a bona fide third party (the “Letter of Intent”) for the Phase II Expansion Space setting forth the proposed terms, covenants and conditions upon which the space will be
leased by the bona fide third party (the “Initial Notice”) and shall include with said notification a copy of the mutually authorized Letter of Intent. Tenant may exercise its right under this Exhibit C by providing Landlord with written
notice of its intention to lease the Phase II Expansion Space and entering into an amendment to this Lease to include the Phase II Expansion Space within the Premises within ten (10) days after receipt of the Initial Notice. In the event that
Tenant fails to provide such notice. Tenant shall be deemed to have waived its option under this Exhibit C and Landlord shall thereafter be free to lease the Phase II Expansion Space to a third party; provided, however, if Landlord does not
consummate a transaction with such bona fide third party within six (6) months of the delivery of the Initial Notice, then the provisions of this Exhibit C and Section J shall continue to apply. 

 

					
	

	  		  	

	LANDLORD	  		  	TENANT

 EXHIBIT D 

Definitions for Termination Option 
 1. The
failure of the product to meet its endpoints can be defined as follows: 
 • The change from Baseline to Week 12 in the weekly mean of
the average daily (24-hr) pain intensity scores on a 0 to 10 NRS scale with 0 indicating ‘no pain’ and 10 indicating ‘pain as bad as you can imagine’. 

• Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index C
(function): Change from Baseline to Week 12 
 • Change from Baseline to Week 16 and then Week 20 and then Week 24 in the weekly mean of
the average daily (24-hr) pain intensity scores on a 0 to 10 NRS scale 
 • Patient Global Impression of Change (PGIC): 7-point scale at
Week 12 
 2. Refuse To File (RTF) Letter — the FDA has identified a material, significant scientific gap in Flexion’s NDA for the Product that
deems the application as incomplete. An RTF is a regulatory action taken at the beginning of an NDA review. 
 3. Complete Response Letter (CRL) —
indicates that there are deficiencies and that the application cannot be approved in its current form. Deficiencies that are not easily addressable with available data and/or commitments to provide required data after approval, could result in
significant delay in the eventual approval of the NDA. 
 4. Non-Approvable Letter — Letter simply stating that the FDA has elected not to approve
Flexion’s product for sale. 

 EXHIBIT E 

Right of First Refusal – Suite 210 Temporary Space 

1. If Tenant exercises its option to expand into the Phase II Expansion Space prior to October 1, 2015, Tenant shall have the exclusive
right of first refusal until September 30, 2016 to expand into the Suite 210 Temporary Space on the conditions hereinafter set forth and to be exercised as hereinafter provided: 

(a) No default by Tenant shall be existing or continuing in the performance of any of the terms, covenants and conditions of
this Lease in respect of a matter as to which notice of default has been given hereunder; provided, however, that in the event of any default that cannot with due diligence be cured prior to the last date on which Tenant is entitled to exercise such
right Tenant may nevertheless exercise such right of first refusal if Tenant shall have proceeded promptly after the service of any notice of default to commence to cure the default, and thereafter completes the curing of the default with due
diligence. 
 (b) Tenant shall lease the Suite 210 Temporary Space on then existing market rental rates and terms. 

2. Tenant shall exercise its right of first refusal in the following manner: Landlord shall notify Tenant at the Premises that Landlord has
entered into a letter of intent with a bona fide third party (the “Letter of Intent”) for the Suite 210 Temporary Space setting forth the proposed terms, covenants and conditions upon which the space will be leased by the bona fide third
party (the “Initial Notice”) and shall include with said notification a copy of the mutually authorized Letter of Intent. Tenant may exercise its right under this Exhibit E by providing Landlord with written notice of its intention to
lease the Suite 210 Temporary Space upon all of the terms and conditions set forth in the Letter of Intent and entering into an amendment to this Lease to include the Suite 210 Temporary Space within the Premises upon such terms and conditions, and
otherwise upon the terms and conditions set forth in this Lease, within five (5) business days after receipt of the Initial Notice. In the event that Tenant fails to provide such notice, Tenant shall be deemed to have waived its option under
this Exhibit E and Landlord shall thereafter be free to lease the Suite 210 Temporary Space to a third party. Notwithstanding anything to the contrary contained herein, if Tenant shall not have previously exercised its rights under this Exhibit E,
Tenant’s rights under this Exhibit E shall cease and be of no further force and effect after September 30, 2016. 
  

					
	

	  		  	

	LANDLORD	  		  	TENANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]